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ABSTRACT 
Diabetes mellitus (DM) and chronic kidney disease (CKD) are both associated with increased 
cardiovascular morbidity and mortality, and the risk is even higher when they are concurrent. 
Both diseases are considered to be prothrombotic states with increased inflammatory activity 
and major disturbances in the hemostasis. Lipid-lowering treatment (LLT) may have 
beneficial effects on inflammation, platelet activation and atherothrombotic mechanisms. 
 
We evaluated the prognostic implications of impaired renal function, measured as estimated 
creatinine clearance (eCrCl), in 808 patients with stable angina pectoris in a post hoc analysis 
of the Angina Prognosis Study In Stockholm (APSIS), which compared metoprolol and 
verapamil treatment in stable angina with a median follow-up of 40 months. A multivariate 
Cox analysis showed an independent prognostic importance of eCrCl for cardiovascular (CV) 
death and for CV death or myocardial infarction (MI). Patients with eCrCl <60 ml/min had a 
doubled risk of suffering CV death or MI, compared to patients with eCrCl ≥90 ml/min.  
We investigated the effects of LLT with simvastatin alone or in combination with ezetimibe 
in 18 patients with an estimated GFR (eGFR) of 15-59 ml/min/1.73m2 (DM-CKD) and 21 
DM patients with eGFR >75 ml/min/1.73m2 (DM-only) in a randomized, double blind, cross-
over study. Parameters reflecting platelet activity, microparticles (MP) formation and 
inflammatory parameters were measured. At baseline, after a placebo run-in period, we found 
signs of increased inflammatory activity, increased platelet activation and hypercoagulability 
in DM-CKD compared to DM-only patients with increased formation of platelet-leukocyte 
aggregates (PLA), elevated levels of proinflammatory cytokines and soluble CD40L 
(sCD40L) in plasma, as well as elevated levels of MPs derived from platelets (PMPs), 
monocytes (MMPs) and endothelial cells. Simvastatin treatment alone reduced the expression 
of P-selectin, tissue factor (TF) and CD40L on PMPs, and TF on MMPs in both patient 
groups. Simvastatin also reduced levels of total procoagulant MPs, PMPs and MMPs as well 
as IFNγ and MCP-1 in DM-CKD but not in DM-only patients. Furthermore, the combination 
of simvastatin+ezetimbe reduced PLA formation and sCD40L levels in DM patients with 
CKD compared to DM-only patients. Most differences between DM-CKD and DM-only 
patients were reduced or disappeared with LLT despite similar lipid levels in the two groups 
both before and during LLT. 
In conclusion, impaired renal function carries independent prognostic information in patients 
with stable angina pectoris, in agreement with findings in other patient categories. Patients 
with CKD should be identified early, as there is need for improved CV risk reduction therapy 
in these high-risk patients. DM patients with CKD stages 3-4 (eGFR 15-59 mL/min/1.73m2) 
have signs of increased inflammatory activity and platelet activation, and hypercoagulability 
compared to DM-patients with normal eGFR. LLT counteracted the differences between 
DM-CKD and DM-only patients, with reduced inflammatory activation and a less 
procoagulant milieu especially in the presence of CKD. This may contribute to the beneficial 
effects of LLT on atherothrombotic complications in DM patients with concurrent CKD.   
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1 INTRODUCTION 
1.1 BACKGROUND 
Diabetes mellitus (DM) is one of the most common causes of chronic kidney disease (CKD) 
mainly as a consequence of the global increase in type 2 DM and obesity (Tuttle 2014). Both 
DM and CKD are associated with increased cardiovascular morbidity and mortality and large 
cohort studies have shown that those with kidney disease predominantly account for the 
increased mortality in patients with both type 1 and type 2 DM (Groop 2009, Afkarian 2013). 
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in patients with 
CKD, and individuals with mild to moderate CKD are more likely to die of CVD than to 
develop end-stage renal disease (Levey 2012). Both CKD and albuminuria are independent 
risk factor for CV mortality both in the general population and in high-risk patients (history 
of hypertension, diabetes, or cardiovascular disease) with an exponentially increasing risk for 
CVD with declining renal function (Chronic Kidney Disease Prognosis 2010, van der Velde 
2011).  
The pathophysiological links between CKD and CVD have been subject to rapidly growing 
interest the last ten years. Patients with CKD have a high prevalence of “traditional” risk 
factors such as diabetes, hypertension and dyslipidaemia. In addition, “non-traditional” risk 
factors such as chronic inflammation, mineral disorders, anemia, increased oxidative stress 
and procoagulant mechanisms may contribute to the excess risk (Stenvinkel 2002, Sarnak 
2003, Shlipak 2005). However, the complex pathophysiological links between CKD and 
CVD are still not fully understood and need to be further explored. 
The Kidney Disease Improving Global Outcomes (KDIGO) statement has defined CKD as 
the presence of kidney damage (i.e., albuminuria) or a decreased glomerular filtration rate 
(GFR) <60ml/min per 1.73m2 during 3 months or more, irrespective of the clinical diagnosis 
(Levey 2012). Since GFR plays an essential role in the pathophysiology of complications, 
CKD is divided into five stages based on GFR: 
Stage Description GFR (ml/min/1.73m2) 
1 Kidney damage with normal renal function >90 
2 Mildly decreased renal function 60-89 
3 Moderately decreased renal function 30-59 
4 Severely decreased renal function 15-29 
5 Kidney failure <15 
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GFR can be estimated (eGFR) by equations based on serum creatinine or cystatin-C (Levey 
2012). 
Albuminuria has an important role in the progression of CKD, and epidemiological studies 
show a graded relationship between albuminuria and mortality as well as kidney outcomes 
(Levey 2012). Since albuminuria is an independent risk factor for CVD morbidity and 
mortality, the classification of CKD has recently been modified by the addition of stages 
based on albuminuria (Levey 2012).  
Lipid-lowering treatment (LLT) with statins reduces cardiovascular morbidity in DM patients 
without (Collins 2003, Colhoun 2004) or with (Collins 2003) cardiovascular disease, as well 
as in patients with non-dialysis dependent CKD (Baigent 2011, Palmer 2012). In patients 
with CKD and no history of MI or coronary revascularization, the SHARP study showed a 17 
% reduction of major atherosclerotic events with simvastatin and ezetimibe co-treatment 
compared to placebo (Baigent 2011). Ezetimibe inhibits intestinal cholesterol absorption and 
is mainly used concomitantly with a statin to further reduce LDL cholesterol (Kalogirou 
2010). Statins seem to have antiinflammatory and antithrombotic effects, which may 
influence markers of coagulation, inflammation and platelet activation independently of their 
lipid-lowering effects, i.e., so-called pleiotropic effects (Bonetti 2003). Ezetimibe may also 
have additional effects on inflammation and coagulation independent of the lipid-lowering 
effect, but this remains controversial (Kalogirou 2010). 
Both DM and CKD are associated with inflammation and have complex disturbances in 
hemostatic function, leading to a prothrombotic state (Hess 2011, Lutz 2014). The present 
work concerns the influence of CKD on inflammatory and hemostatic mechanisms in patients 
with DM and the effects of LLT. 
1.2 PLATELET FUNCTION, PLATELET-LEUKOCYTE INTERACTIONS AND 
INFLAMMATION – IMPORTANCE IN ATHEROSCLEROSIS AND 
THROMBOSIS 
Platelets have a central role in the pathophysiology of atherosclerosis and thrombosis, in 
interaction with coagulation, endothelial function and inflammation (Gawaz 2005). 
1.2.1 Platelet physiology 
Platelets are small dynamic anuclear cell fragments formed from megakaryocytes and with a 
lifespan of approximately 7-10 days. Around 2/3 of the platelets circulate in the blood and the 
remaining 1/3 are stored in the spleen. In the absence of vessel injury or other stimuli 
platelets circulate in the blood in a resting discoid shape; they are normally inhibited from 
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activation by nitric oxide (NO) and prostaglandin I2  (prostacyclin) released from healthy 
endothelial cells. The primary function of the platelets is to stop hemorrhage after damage to 
the vessel wall (Jurk 2005). Platelets contain three different secretory granules: α-granules, 
dense granules and lysosomes, in which a large number of proteins with various biological 
functions are stored. α-Granules are the most abundant ones and contain proteins such as P-
selectin, von Willebrand factor (VWF), β-thromboglobulin, fibrinogen, GPIIb/IIIa, Factor V, 
Factor X, plasminogen activator inhibitor (PAI-1) and CD40 ligand (CD40L). The dense 
granules contain adenosine diphosphate (ADP), serotonin and Ca++, and lysosomes contain 
hydrolytic enzymes (Jurk 2005). 
The platelet cytoplasmic membrane consists of a bilayer of polarized phospholipids 
containing arachidonic acid, which is released and converted to thromboxane A2 (TxA2) via 
cyclooxygenase-1 (COX-1) during platelet activation. The external layer of the platelet 
contains numerous glycoproteins (e.g., GPIV, GPIb/V/IX and GPIIb/IIIa). These 
glycoproteins act as receptors for several ligands and are important for platelet adhesion and 
activation. Platelets also have other membrane receptors for a number of agonists. 
1.2.2 Platelet activation  
Adhesion of resting platelets to a damaged vessel wall is the first step of primary hemostasis 
(Jurk 2005). The adhesion is mainly mediated by interactions between the GPIb/V/IX 
receptor complex on the platelet surface and VWF, and interactions between GPVI and 
collagen at the site of endothelial damage. The adhesion leads to a shape change of the 
platelet from a smooth disc to a small sphere with pseudopods, and then spreading of the 
platelets on the damaged vessel wall. VWF plays an important role in platelet adhesion as it 
binds to both collagen and two major platelet receptors (GPIb/V/IX and GPIIb/IIIa) (Davi 
2007). VWF supports platelet adhesion predominately during high shear flow.  
Upon shape-change and activation of the adhering platelets there is secretion of granule 
components and activation of the fibrinogen receptor (GPIIb/IIIa) leading to fibrinogen 
binding and platelet-platelet aggregation. Resting platelets are not able to bind fibrinogen. 
Local platelet activators, such as ADP, TxA2, serotonin and thrombin, help to recruit 
additional circulating platelet to the primary hemostatic plug. The release of ADP and TxA2 
from activated platelets provides an important positive feed-back to reinforce platelet shape 
change, activation and aggregation, and secretion of granule contents. Thrombin is the most 
potent endogenous platelet activator and acts through stimulation of specific thrombin 
receptors (PAR-1 and PAR-4) on the platelet surface (Davi 2007). Thrombin activates 
platelets at lower concentrations than those required to activate the coagulation cascade. 
The primary platelet plug is rather unstable and needs reinforcing, which is the goal of the 
secondary hemostasis. Secondary hemostasis involves activation of the coagulation cascade 
and thrombin-mediated conversion of fibrinogen to fibrin, leading to formation of a fibrin 
network and consolidation of the blood clot. Fig 1 shows a schematic presentation of platelet 
activation in the atherosclerotic plaque. 
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Activated platelets have a procoagulant surface, mainly because of increased expression of 
the anionic phospholipid phosphatidylserine (PS) on the external layer of the platelet 
membrane, allowing assembly and activation of calcium-binding coagulation factors, as a 
result of its negative charge. This activation of the coagulation cascade leads to a burst of 
thrombin generation thus creating a more stable clot (Jurk 2005). Furthermore, platelet 
binding to monocytes leads to increased tissue factor (TF) expression and thrombin 
generation. Thus, there are important links between platelets, leukocytes and blood 
coagulation. 
 
 
 
 
Figure 1. Schematic presentation of platelet activation in an atherosclerotic vessel. 
Figure 2. Discoid resting platelet (A) and early activated platelet (B). 
Reprinted from Platelets (Third edition) 2013 with permission from Elsevier. 
A B 
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1.2.3 The coagulation system 
The cell-based model of hemostasis (Fig 3) suggests that coagulation consists of three stages, 
which occur on different cell surfaces: 1) Initiation, which occurs on a TF bearing cell, 2) 
Amplification, in which platelets and cofactors are activated; and 3) Propagation, in which 
large amounts of thrombin are generated on the platelet surface (Hoffman 2001). 
 
 
TF (FIII) is essential for blood coagulation (Mackman 2009). At the time of vessel injury, TF 
is released into plasma by cells in the vessel wall and activates the clotting cascade. 
Atherosclerotic plaques contain large amounts of TF, which is exposed to the circulation 
upon plaque rupture. TF may also be expressed by circulating monocytes, endothelial cells 
and circulating microparticles (MPs) in the presence of inflammation, and TF also contributes 
to inflammation by various mechanisms such as increased release of proinflammatory 
cytokines (Mackman 2009). During the initiation phase, when TF comes in contact with 
plasma it binds to FVII and forms the TF-FVIIa complex which activates FX to FXa and FIX 
to FIXa. On the cell surface, mainly on platelets, FXa binds to FVa and forms the 
prothrombinase complex, which converts prothrombin to small amounts of active thrombin 
(FIIa) by cleavage. Since thrombin is the most potent platelet activator, the small amounts of 
thrombin that are generated lead to intensified platelet adhesion and activation at the site of 
injury. The amplification phase occurs on the platelet surface as it becomes activated. During 
activation platelets release FV in a partially activated form. FV is then fully activated by 
Figure 3. The cell-based model of the hemostasis. 
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thrombin or FXa. Thrombin also induces the release of FVIII from VWF which leads to 
activation of FVIII to FVIIIa. During the propagation phase, the FVIIIa/IXa complex 
activates FX on the platelet surface, leading to formation of FXa/FVa complexes which may 
initiate the large burst of thrombin generation needed for conversion of fibrinogen to fibrin 
and the subsequent formation of a stable fibrin clot (Hoffman 2001). 
The coagulation system is tightly regulated by inhibiting factors. Antithrombin, protein S and 
Tissue factor pathway inhibitor (TFPI) are three major important inhibitors (Versteeg 2013). 
The fibrinolytic system (Fig 3) is designed to resolve the stable fibrin clot and thus prevent 
fibrin accumulation in the vessels. The most important compounds in the fibrinolytic system 
are plasmin, tissue plasminogen activator (tPA) and PAI-1. Plasmin is the protease that 
cleaves fibrin and is activated by tPA from its inactive form plasminogen. PAI-1 is the most 
important fibrinolysis inhibitor and forms a stable complex with tPA which blocks further 
tPA-dependent plasmin generation. 
1.2.4 Platelet-leukocyte aggregates 
Platelet-leukocyte interactions form a link between coagulation and inflammation (Li 2000, 
Ghasemzadeh 2013). Platelets and leukocytes may influence each other via direct cellular 
conjugation (to form platelet-leukocyte aggregates; PLA) and/or via the release of soluble 
mediators without PLA formation (Li 2000). Platelet binding increases the ability of 
leukocytes to adhere to and invade the vessel wall, and may thus promote the atherosclerotic 
process. Platelet-released substances (e.g., TxA2 and ADP) can activate leukocytes and, vice 
versa, leukocyte-released substances (e.g., platelet activating factor, superoxide anions, and 
enzymes such as elastase and cathepsin G) can activate platelets. There may also be 
reciprocal inhibition among these cell types via release of NO. As noted above, platelet 
binding to monocytes also facilitates thrombin generation. Thus, platelets and leukocytes 
interact in many important ways, and platelet-leukocyte aggregation seems to be important in 
atherothrombotic diseases (Li 2000, Cerletti 2012, Ghasemzadeh 2013). 
P-selectin is stored in the α-granules of the platelets and is released upon platelet activation. 
P-selectin mediates interactions between platelets, leukocytes and endothelial cells and is the 
most important receptor for platelet-leukocyte conjugation through its ligand P-selectin 
glycoprotein 1 (PSGL-1). CD40-CD40L interactions also enhance PLA formation (Cerletti 
2012). Increased PLA formation has been found in conditions with high cardiovascular risk 
and increased inflammatory activity, such as acute coronary syndromes (Brambilla 2008), 
stable coronary artery disease (Furman 1998) and in DM (Hu 2004). 
1.2.5 The CD40-CD40L system 
The CD40-CD40L system represents an interesting connection between platelets and 
inflammation (Antoniades 2009). This system is a key mediator of cell communication in the 
immune system and may also be involved in the progression of established atherosclerotic 
lesions to more advanced and unstable lesions. Both CD40L and its soluble form sCD40L 
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interact with CD40 expressed on macrophages, endothelial cells and vascular smooth muscle 
cells, resulting in proinflammatory and prothrombotic effects that include increased platelet 
activation and aggregation, and platelet-leukocyte interactions. Activated platelets are found 
to be the main source of sCD40L in plasma (Antoniades 2009, Lievens 2010), and elevated 
plasma levels of sCD40L predict future CV risk (Antoniades 2009). CD40-CD40L 
interactions seem to promote atherosclerosis and atherothrombosis (Lievens 2010). Patients 
with DM (Lim 2004) and patients with CKD (Schwabe 1999) have been found to have 
elevated levels of sCD40L, compared to healthy controls. 
1.2.6 Microparticles 
Microparticles (MPs) are small (0.1-1.0 µm in diameter) particles found in the blood stream, 
which are released from cell membranes upon activation and/or apoptosis. MPs are derived 
from various cell types such as platelets, endothelial cells, leukocytes or erythrocytes, and 
may contain various cytokines, growth factors and proteases depending on their origin. 
Interestingly, MPs can display biological activities associated with thrombosis, inflammation 
and immune responses, and they appear to be both a contributor to, and a consequence of, 
inflammation (Burger 2013). MPs have procoagulant activity through the expression of 
negatively charged phospholipids (phosphatidylserine, PS), which facilitates the assembly of 
coagulation factors and promotes thrombin generation (Burger 2013), and they can also 
expose TF, the primary initiator of blood coagulation (Owens 2011). Platelet derived MPs 
(PMPs) are the most abundant type of MP in the circulation, and upon release they can 
expose several proteins and cytokines such as P-selectin, CD40L and TF. 
Elevated plasma levels of platelet, endothelial or leukocyte derived MPs have been found in 
patients with cardiovascular risk factors and disorders, such as hypertension, DM, acute 
coronary syndromes and stroke (Burger 2013). CKD has also been associated with elevated 
levels of MPs (Ando 2002, Amabile 2005, Faure 2006, Amabile 2012). 
1.3 HEMOSTASIS IN DIABETES MELLITUS 
DM is a prothrombotic state with increased platelet activation, activation of the coagulation 
system, decreased fibrinolytic capacity and increased inflammatory activity (Ferreiro 2010, 
Hess 2011). Diabetic patients have hyperreactive platelets with exaggerated adhesion, 
aggregation and thrombin and TxA2 generation, higher levels of soluble P-selectin in plasma 
(Yngen 2004, Ferreiro 2010), and increased platelet-leukocyte cross-talk (Hu 2004). 
1.4 HEMOSTASIS IN CHRONIC KIDNEY DISEASE – BLEEDING AND 
CLOTTING 
Patients with CKD have major disturbances in their hemostasis, which result either in a 
hypercoagulable state with an increased risk of suffering thrombotic complications 
(myocardial infarction, acute coronary syndromes, cerebrovascular events, and venous 
thrombosis), or in an increased risk of bleeding (Lutz 2014). The reasons for these 
disturbances are complex and involve several different components of the coagulation system 
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such as the coagulation cascade, the fibrinolytic system, the platelets, the endothelium and the 
vessel wall (Lutz 2014). Factors involved in the procoagulant state in patients with chronic 
kidney disease are shown in Table 1. The exact protrombotic mechanisms responsible for the 
increased cardiovascular risk in CKD are, however, still not fully understood. 
1.4.1 Platelets in CKD 
The increased risk of bleeding frequently seen in CKD, especially in patients with severe 
renal impairment, has been associated with altered platelet physiology, leading to platelet 
dysfunction and impaired platelet-vessel wall interactions with increased risk of cutaneous, 
mucosal, and serosal bleeding as typical manifestations (Boccardo 2004). Several 
mechanisms are thought to contribute to platelet dysfunction in severe CKD, such as altered 
platelet granule contents, altered ADP and serotonin release, impaired function of GPIIb/IIIa, 
decreased GPIb, defective VWF and decreased binding of VWF and fibrinogen to activated 
platelets (Boccardo 2004). 
During the last 10 years, when the connection between CKD and atherothrombotic disease 
has been in focus, an increasing number of studies have shown hyperreactive platelets with 
increased platelet activation and aggregation in patients with CKD (Landray 2004, Thijs 
2008, Woo 2011, Gremmel 2013, Yagmur 2013), suggesting that platelet activation may play 
a role in atherothrombosis in CKD. A majority of these studies has included high-risk patients 
with known cardiovascular disease. The pathophysiology behind increased platelet activation 
and aggregation in CKD is, however, not fully known. Increased exposure of PS on the 
platelet surface, and increased levels of P-selectin and GPIIb/IIIa are possible contributors 
(Lutz 2014, Bonomini 2004). 
1.4.2 The coagulation system in CKD 
Several disturbances in the coagulation system have been found in patients with CKD, such 
as elevated levels of fibrinogen, TF, PAI-1, VWF and coagulation factors XIIa and VIIa, as 
well as reduced levels of tPA and antithrombin activity, suggesting a prothrombotic state with 
impaired fibrinolysis (Jalal 2010, Lutz 2014).  
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Table 1. Factors involved in the procoagulant state in CKD 
 Decreased NO production Moody 2012 (Review) 
Hypoxia Moody 2012 
Shear stress Moody 2012 
Chronic inflammation Stenvinkel 2002, Landray 2004 
Increased VWF Jalal 2010 (Review) 
Increased platelet phosphatidylserine  Lutz 2014 (Review), Bonomini 2004 
Increased platelet p-selectin Jalal 2010 (Review), Lutz 2014  
Increased GPIIb/IIIa Lutz 2014, Jalal 2010 
Increased sCD40L Schwabe 1999 
Increased MP formation Ando 2002, Faure 2006,  
Increased TF Pawlak 2009 
Increased factor XIIa Lutz 2014 
Increased factor VIIa Lutz 2014  
Increased fibrinogen Lutz 2014, Jalal 2010 
Increased tPA Lutz 2014, Jalal 2010 
Decreased PAI-1 Lutz 2014, Jalal 2010 
Increased acivated protein C Lutz 2014, Jalal 2010 
Increased thrombin-antithrombin complexes Lutz 2014 
Increased D-dimer levels Lutz 2014, Jalal 2010 
Decreased antithrombin Lutz 2014 
 
Plasma fibrinogen is an independent marker for cardiovascular disease (Ariens 2013), and 
elevated levels of fibrinogen have been shown in patients with CKD (Jalal 2010). In addition, 
activation of the renin-angiotensin-aldosterone system (RAAS) has been associated with 
elevated levels of fibrinogen, D-dimer and PAI-1 (Jalal 2010, Lutz 2014). Thus, there seem to 
be close links between blood coagulation, platelets, endothelial dysfunction and inflammation 
which lead to the hypercoagulable state in CKD. 
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1.5 THE ENDOTHELIUM IN DM AND CKD 
The endothelium is essential in vascular biology and serves as a barrier that separates blood 
from the underlying tissue. It regulates a complex balance of factors to maintain vascular 
hemostasis which involve the regulation of vascular permeability, vessel tone, cell adhesion 
and blood hemostasis. A balanced production/expression of vasodilating (i.e., NO and 
prostacyklin) and vasocontricting substances (i.e., endothelin-1, angiotensin II and TxA2) 
characterizes the healthy, normal endothelium. The endothelium also produces adhesion 
molecules for platelets (i.e, VWF and P-selectin) and leukocytes (ICAM-1, VCAM-1 and E-
selectin), anticoagulants (TFPI), and fibrinolytic factors (tPA, thrombomodulin and protein S) 
and inhibitors (PAI-1). 
At sites of vessel injury or during long exposure to risk factors such as chronic inflammation, 
hypertension, hyperlipidemia or hyperglycemia, the properties of the endothelium change 
from a vasodilatory, anticoagulant state, towards a vasocontrictive, proinflammatory, 
procoagulant state. This endothelial dysfunction (or activation) leads to increased 
adhesiveness of leukocytes and platelets, increased permeability and endothelial production 
of cytokines, growth factors and vasoactive molecules (Ross 1999).  Endothelial dysfunction 
plays an important role in the development of atherosclerosis and correlates with 
cardiovascular diseases (Ross 1999). Circulating endothelial MPs shed from endothelial cells 
upon activation are emerging as an interesting marker of endothelial function. 
Disturbed endothelial function is very common in both DM and CKD (Moody 2012, Roberts 
2013), and is considered to be a major contributor to both micro- and macrovascular 
complications in DM (Roberts 2013). Endothelial dysfunction caused by chronic 
inflammation and oxidative stress is thought to be an early and important feature in CKD, and 
is considered to be one of the major pathophysiological mechanisms connecting CKD and 
CVD (Moody 2012). However, this relationship has not been fully proven in clinical studies, 
especially not in early CKD stages, and data is confounded by coexisting diseases such as 
DM and hypertension, which are independently associated with endothelial dysfunction 
(Moody 2012). However, elevated levels of biomarkers for endothelial dysfunction such as 
VCAM-1, VWF, thrombomoduline, tPA and PAI-1 have been associated with CKD and 
diabetic nephropathy (Jalal 2010, Navarro-Gonzalez 2011, Moody 2012). 
1.6 DYSLIPIDEMIA IN DM AND CKD 
Both DM and CKD are associated with hypertriglyceridemia, lower HDL-cholesterol, higher 
VLDL-cholesterol, normal levels of LDL-cholesterol, but elevated levels of small dense LDL 
particles (Siegel 1996, Tsimihodimos 2008). 
1.7 INFLAMMATION IN DM AND CKD 
DM and CKD are both clearly associated increased inflammatory activity (Schmidt 1999, 
Stenvinkel 2002, Landray 2004). Inflammation is a major pathogenic mechanism in the 
development of diabetic nephropathy involving increased chemokine production (i.e, MCP-
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1), increased proinflammatory cytokine production (i.e., interleukin (IL)-1, IL6, IL 18, 
TNFα), increased levels of adhesion molecules (i.e, VCAM-1, ICAM-1), infiltration of 
inflammatory cells in the kidney, and tissue damage (Navarro-Gonzalez 2011). 
1.8 INFLAMMATION IN ATHEROSCLEROSIS AND THROMBOSIS 
Inflammation is closely involved in the pathogenesis of atherosclerosis (Ross 1999). In the 
initiation phase, infiltration and accumulation of modified LDL particles activates the 
endothelium and starts an inflammatory process in the artery wall with expression of 
leukocyte adhesion molecules, in response to pro-inflammatory cytokines. The modified 
LDL particles are taken up by scavenger receptors on macrophages, which then evolve into 
foam cells. After adhesion to the vascular endothelium, chemokines stimulate leukocyte 
migration into the subendothelial site of inflammation. The chemokine monocyte 
chemoattractant protein-1 (MCP-1) is important for the infiltration of monocytes into early 
atherosclerotic lesions. The activated immune cells then produce proinflammatory cytokines, 
which synergistically amplify the inflammatory response and tissue damage (Hansson 2005). 
Under normal physiological conditions, platelets do not adhere to the vascular endothelium, 
but under inflammatory conditions they can adhere to the activated but intact endothelium 
(Gawaz 2005). After platelet adhesion to the endothelium, platelets secrete proinflammatory 
cytokines stored in the granules, such as interleukin Iβ and CD40L, adhesion molecules and 
chemokines, leading to endothelial inflammation (Henn 1998). Adherent platelets then recruit 
circulating leukocytes, activate them and thereby initiate leukocyte transmigration through 
the vessel wall with ensuing foam cell formation (Gawaz 2005). Thus, platelets contribute to 
the inflammatory milieu that promotes atherosclerotic plaque formation. 
1.9 ANTIINFLAMMATORY AND ANTICOAGULANT EFFECTS OF LIPID-
LOWERING TREATMENT 
The question of possible additional effects of statins beyond their lipid-lowering effect, i.e., 
pleiotropic effects, has been intensely debated. Statins are suggested to have favourable 
effects on platelet adhesion, thrombosis, endothelial function, inflammation and plaque 
stability, independently of their cholesterol lowering effect (Bonetti 2003). Statins block the 
conversion of HMG-CoA to mevalonic acid, leading to reduced synthesis of cholesterol (Fig 
4). Many of the pleiotropic effects observed in various studies have been shown to be related 
to inhibition of the synthesis of isoprenoid intermediates of the mevalonate pathway (Bonetti 
2003), which may, e.g., influence cellular proliferation. 
 
 
 
 
 
Figure 4: The mevalonate metabolism pathway 
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Statins have also been found to exert antithrombotic effects through reduced monocyte TF 
expression (Owens 2014) and reduced thrombin generation (Undas 2005). One of the best 
documented non-lipid effects of statins is improvement of parameters associated with 
endothelial function (Bonetti 2003). This is likely achieved by both enhancement of 
vasodilator and attenuation of vasoconstrictor activity in the vessel wall. 
Ezetimibe may also have additional, pleiotropic effects on inflammation and coagulation 
independently of the lipid-lowering effect, but this remains controversial (Kalogirou 2010).  
 
Figure 4.The mevalonate metabolism pathway 
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2 AIMS OF THE PROJECT 
 
The overall aim of this project was to contribute to the improvement of cardiovascular risk 
reduction management in patients with DM and CKD. 
 
Specific aims of this work were: 
• To evaluate the prognostic importance of impaired renal function in patients with 
stable angina pectoris (Paper I). 
 
• To study the impact of CKD on platelet function and platelet-leukocyte interactions, 
inflammatory parameters and circulating microparticles in patients with DM (Papers 
II-IV). 
 
• To study effects of lipid-lowering treatment with simvastatin alone or with the 
combination of simvastatin+ezetimibe in patients with diabetes DM with and without 
CKD with regard to: 
o platelet function and platelet-leukocyte aggregation, and inflammatory 
parameters (Paper II). 
o proinflammatory cytokines, chemokines and adhesion molecules (Paper III). 
o circulating microparticles (Paper IV). 
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3 PATIENTS & METHODS 
3.1 STUDY DESIGN AND POPULATION 
3.1.1 Paper I 
This was a post hoc analysis from the Angina Prognosis Study in Stockholm (APSIS) with 
the purpose to evaluate the prognostic implications of renal dysfunction in patients with 
stable angina pectoris. The APSIS was a prospective, randomized, single center trial 
investigating the prognosis of 809 patients (248 females) with stable angina pectoris treated 
double-blindly with metoprolol or verapamil (Rehnqvist 1996). Patients aged < 70 years with 
clinically diagnosed angina pectoris were included and followed at the Heart Research 
Laboratory at Danderyd Hospital during 1987-1993; the mean follow-up was 40 months. 
Exclusion criteria included myocardial infarction (MI) within the last 3 years (ß-blocker 
treatment was considered to be indicated among such patients), anticipated need for 
revascularisation within 1 month, significant valvular disease, severe congestive heart failure 
or risk for poor compliance. The primary end-point was CV death or nonfatal MI. 
At baseline, serum creatinine (SCr) was measured and the estimated creatinine clearance 
(eCrCl) was calculated by the Cockcroft-Gault formula in 808 of the 809 patients. Outcomes 
were compared for three groups according to their renal function: eCrCl >90 ml/min, eCrCl 
60-89 ml/min and eCrCl 30-59 ml/min.  
3.1.2 Papers II-IV 
The study had a randomized, double blind, cross-over design with an initial single-blind 6-
week wash-out period with placebo followed by two 8-10 weeks double blind periods of 
LLT. Investigations were performed at baseline and after each treatment period (Fig 5). The 
target dose for simvastatin was 40 mg daily. If necessary, patients could start with a lower 
dose. Dose titration was completed after within 4-6 weeks. The ezetimibe dose was 10 mg 
daily. To minimize confounding by variable co-treatment, all patients received 75 mg aspirin 
(Trombyl®) daily, and patients not on an ACE-inhibitor or an angiotensin II receptor blocker 
(ARB) also received enalapril 5-10 mg daily during the entire study. 
 Figure 5. Study design papers II-IV 
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The MDRD formula (Levey 1999) was used to calculate the eGFR. A total of 39 DM patients 
were included; 18 patients with an eGFR of 15-59 ml/min x 1.73m2, i.e., CDK stages 3-4,  
(DM-CKD group) and 21 patients with eGFR >75 ml/min x 1.73 m2 (DM-only group). 
Patients were recruited from the Department of Nephrology and the Diabetology Unit, 
Danderyd Hospital, and from the Diabetology Unit, South Hospital, Stockholm, Sweden. 
Major exclusion criteria were previous MI, coronary revascularisation, or stroke, or poor 
metabolic control (HbA1c >83mmol/mol). The patient groups were matched for age and sex. 
3.2 LABORATORY INVESTIGATIONS 
3.2.1 Blood sampling 
§ Paper I 
Venous blood was collected between 8 and 10 am, after an overnight fast. 
 
§ Papers II-IV 
The patients were asked to have a light breakfast and to abstain from alcohol, tobacco 
and caffeine on days of sampling. Antecubital venous blood was collected in citrate, 
EDTA and heparin tubes by the vacutainer technique after 30 min of semi-recumbent 
rest. Plasma was collected after centrifugation at 1400 x g for 10 min at 4° C (for 
EDTA tubes after an additional centrifugation at 1400 x g for 15 min at 4°) and frozen 
at –80°C until analysis. 
3.2.2 Assessment of platelet function (Paper II) 
Unstimulated and agonist-induced platelet P-selectin expression and PAC-1 (activated 
fibrinogen receptor antibody) binding were determined by whole blood flow cytometry (Li 
1999). Within 5 min of collection, aliquots of 5 ųl of citrated whole blood were added to 45 
ųl of Hepes buffered saline containing appropriately diluted antibodies and agonists and 
incubated at room temperature for 20 min. Samples were fixed and diluted with 0.5% 
formaldehyde in saline before analysis using a Coulter EPICS XL-MCL flow cytometer. 
Platelets were identified by their light scattering signal and by staining with FITC-conjugated 
anti CD42a (GPIX) MAb (Becton Dickinson). Platelet activation was determined using RPE-
conjugated anti-P-selectin MabAC1.2  (Becton Dickinson) and FITC-conjugated PAC-1 
binding (Becton Dickinson). Platelet agonists were ADP (0.1-10 µM), a collagen related 
peptide (CRP-18/I; 0.025-10 µg/mL) which activates platelet GPVI, and human α-thrombin 
(0.01-0.08 U/mL). In thrombin-stimulated samples, GPRP (Gly-Pro-Arg-Pro peptide, Sigma, 
St Louis, MO, USA) at a final concentration of 0.8 mM was added to prevent clotting. 
Results are presented as percentages of platelets expressing P-selectin or binding PAC-1 in 
dose-response curves induced by ADP, thrombin and CRP-18/i (a collagen-related peptide 
stimulating GPVI). 
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3.2.3 Platelet-leukocyte aggregation (Paper II) 
PLAs were analysed using whole blood flow cytometric methodology causing little or no 
artificial generation of PLAs in vitro, thus reflecting circulating PLAs (Li 1999). Leukocytes 
were identified by anti CD45-PE (Beckman Coulter), and further discriminated by their side 
scattering characteristics into lymphocytes, monocytes and neutrophils. Monocytes were also 
identified by anti CD14-PC5 (Beckman Coulter). Total leukocytes and different subgroups 
were then subjected to two-colour analysis (RPE-CD45 versus FITC-GPIX (CD42a)) to 
discriminate platelet-coupled and platelet-free leukocytes. Data are presented as percentages 
of platelet-conjugated leukocytes in the total leukocyte population (PLA), and among 
neutrophils (P-Neu), monocytes (P-Mon) and lymphocytes (P-Lym) without and with ex vivo 
stimulation by ADP (1 µM), CRP-18/I (1 µg/mL) and thrombin (0.04 U/mL). 
3.2.4 Microparticles analyses (Paper IV) 
Platelet poor plasma samples (double centrifuged EDTA tubes) that had been stored at -80°C 
were thawed and centrifuged at 2000 x g for 20 min at room temperature. The supernatant 
was then re-centrifuged at 13 000 x g for 2 min at room temperature. 20 µl from the 
supernatant were then stained and prepared for flow cytometric analysis. MPs were measured 
by a Beckman Gallios flow cytometer (Beckman Coulter, Brea, CA, USA). The MP gate was 
determined using Megamix beads (BioCytex, Marseille, France). MPs were initially defined 
as particles less than 1.0 µm in size and negative to phalloidin in order to exclude cell 
membrane fragments (Mobarrez 2010). All MPs, regardless of cellular origin were defined as 
phosphatidylserine positive (PS+) MPs. Platelet-MPs (PMPs) were defined as PS+CD41+, 
endothelial-MPs (EMPs) as PS+CD62E+ (E-selectin positive) or PS+CD144+, and 
monocyte-MPs (MMPs) as PS+CD14+. Further phenotyping included measurements of TF 
(CD142) on PMPs, EMPs and MMPs and CD40L (CD154) on PMPs. Due to incompatibility 
of flow cytometric dyes, lactadherin could not be used when TF (CD142) expression was 
measured (both are only available as FITC labeled). Thus, the TF positive MPs were defined 
by size (<1.0 µm) and co-expression of CD142 together with CD41, CD62E or CD14. The 
absolute numbers of MPs were calculated by the following formula: (MPs counted x standard 
beads/L)/standard beads counted (FlowCount, Beckman Coulter). Data are expressed as 106 
MPs/L. 
3.2.5 Biochemical analyses 
Paper I 
SCr was analysed by the Department of Clinical Chemistry, Danderyd Hospital, using an 
automated Jaffe method. 
Papers II-IV 
HbA1c, creatine kinase (CK), creatinine, potassium, urea nitrogen, cystatin-C, ALAT, total, 
LDL and HDL cholesterol, triglycerides, blood glucose, C-reactive protein (hsCRP; high 
sensitivity assay), hemoglobin, platelet counts, leukocyte differential counts and the urinary 
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albumin/creatinine ratio (ACR) were assessed by standard methods (Clinical Chemistry, 
Karolinska University Hospital, Stockholm, Sweden). Enzyme immunoassays were used to 
determine plasma sCD40L (R&D Systems), VWF antigen (Asserachrom, Diagnostica Stago, 
France), elastase (DPC Biermann GmbH, Bad Nauheim, Germany) and soluble vascular cell 
adhesion molecule-1 (sVCAM-1) (R&D Systems) levels. Interferon-γ (IFNγ), tumor necrosis 
factor-α (TNFα) and monocyte chemoattractant protein-1 (MCP-1) were analyzed using a 
high throughput automated biochip immunoassay system (EvidenceH with the Evidence 
Investigator TM equipment, Randox Laboratories Ltd, Crumlin, UK).  
3.3 STATISTICAL ANALYSES 
Paper I 
Data are presented as mean values ± SD or percentages. Statistical comparisons were 
performed by nonparametric tests (Mann-Whitney U-test, chi-square test). Associations 
between measured variables and events were investigated by univariate proportional hazard 
(Cox) analyses, and Kaplan-Meier plots with chi-square tests and log rank statistics. In a 
second step, variables that showed some relationship to events were further evaluated using a 
multivariate Cox proportional hazard model including adjustments for known risk factors 
(sex, age, previous MI, hypertension and DM). Analyses were performed according to the 
principle of intention-to-treat. 
Papers II-IV 
Data are presented as mean ± SD (SEM in the figures for increased clarity), or median values 
and inter-quartile ranges for skewed variables. Multiple comparisons of continuous data were 
performed by repeated measures ANOVA, after validation for normal distribution by use of 
the Shapiro Wilk test, and with Fisher´s post hoc test to control for multiplicity. Skewed data 
were logarithmically transformed before the analysis. Student’s t-test or Mann–Whitney’s U-
test, as appropriate, were used to evaluate differences between two independent groups. 
Correlations between variables were assessed by linear regression analyses and calculations 
of the Pearson correlation coefficient. Variables in contingency tables were tested by the chi-
square test. 
Analyses were performed using the SAS system for Windows 9.2 (SAS Institute Inc., Cary, 
NC, USA) or STATISTICA software (Statsoft, Tulsa, OK, USA). A p-value of <0.05 was 
considered to be statistically significant. 
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4 RESULTS & DISUSSION 
4.1 PAPER I 
Estimated CrCl <60 ml/min was common in patients with stable angina 
In the present study population of 808 patients with clinically diagnosed stable angina 
pectoris who were treated with metoprolol or verapamil, the mean eCrCl was 78±21 ml/min 
(68±17 for women and 82±21 for men) and the mean sCr was 97±18 µmol/L at baseline. 
Their mean age was 59.4±7.4 years. 164 patients (91 women; 20% of the total study 
population) had an eCrCl below 60 ml/min and the lowest eCrCl was 34 ml/min, i.e., CKD 
stage 3 according to current guidelines. 
Patients with low eCrCl were older, and more likely to be women and non-smokers. The 
prevalence of previous MI, hypertension and DM was similar in the three renal function 
groups. The age of male and female patients in the lowest eCrCl group did not differ (65 ± 4 
and 64 ± 5 years respectively). Baseline characteristics of the patients in the three renal 
function groups are shown in Table 1, Paper I (Appendices). 
Prognostic implications of eCrCl regarding CV death and MI 
During follow up, 38 patients suffered CV death and 31 patients a nonfatal MI. In the 
univariate analysis a low eCrCl was related to a higher risk for the combined end-point of CV 
death and MI for men (p=0.036), but not for all patients (p=0.307). There was a graded 
inverse relationship between eCrCl and CV-death or MI among men (Fig 6). No separate 
analysis of female patients was performed, since only 10 women suffered CV death or MI. 
Univariate analyses of the relationship between eCrCl and outcomes for all patients were 
confounded by the higher prevalence of low eCrCl among women, who had a better 
prognosis in the APSIS study. When analysed with a multivariate Cox-model including 
known risk factors such as sex, age, previous MI, hypertension and DM, we found an 
independent prognostic importance of eCrCl for both CV death (p=0.046) and the combined 
endpoint CV death and nonfatal MI (p=0.042) for all patients (Table 2). 
Table 2. Results of the Cox proportional hazard analysis. The following co-variates were used: age, 
sex, previous MI, hypertenison and diabetes mellitus. Results are presented for subgroup 
comparisons, and for eCrCl as a continuous variable. 
 
 CV death + nonfatal MI 
 
Cv death 
 HR 95% CI of HR p-value HR 95% CI of HR p-value 
Continuous variable 
analysis 
      
  eCrCl (1ml/min diff) 0.984 0.969-0.999 0.042 0.979 0.959-1.000 0.046 
Renal function subgroups       
  eCrCl ≥90 ml/min 1.000   1.000   
  eCrCl 60-89 ml/min 1.529 0.768-3.045 0.227 2.011 0.769-5.257 0.155 
  eCrCl <60 ml/min 1.986 0.865-4.557 0.106 2.824 0.898-8.883 0.076 
eCrCl, estimated creatinine clearence; CV, cardiovascular; MI, myocardial infarction; CI, confidence interval;  
HR, hazard ratio 
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When analysed as a continuous variable, a 1 ml/min decrease in eCrCl was associated with a 
1.6 (0.1 to 3.1) % increase in the risk of suffering CV death or nonfatal MI, and a 2.1 (0 to 
4.1) % increase in the risk for CV death alone. Patients with eCrCl <60 ml/min had a 
doubling of the risk of suffering CV death or nonfatal MI, compared to patients with eCrCl ≥ 
90 ml/min. For CV death alone the relationship was steeper with a three-fold increase in risk 
among patients with the lowest compared to the highest eCrCl (Table 2).  
The randomized study treatment (metoprolol vs. verapamil) did not confound the 
relationships between renal function and CV events (see Paper I for further details). 
Discussion 
This study showed that impaired renal function carried significant prognostic information 
regarding CV death and non-fatal MI in patients with stable angina pectoris. This is in 
agreement with previous findings in patients with other categories of coronary artery disease 
(Al Suwaidi 2002, Best 2002, Anavekar 2004, Gibson 2004), as well as in the normal 
population (Go 2004, Weiner 2004), but had not been shown before in patients with stable 
Figure 6. Kaplan-Meier plots for the 
cumulative proportion of all patients 
without CV death or MI (A) and for 
the cumulative proportion of male 
patients without CV death or MI (B). 
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angina. Impaired renal function, as estimated by GFR or CrCl is also associated with an 
increased risk in other cardiovascular diseases such as atrial fibrillation (Alonso 2011) and 
heart failure (Kottgen 2007). The prognostic impact of impaired renal function was graded, in 
agreement with findings of an exponentially increasing risk for CVD with declining renal 
function (van der Velde 2011).   
Twenty % of the patients in our study had an eCrCl <60 ml/min. In the normal population, 
the prevalence of moderately impaired renal function (eGFR 30-59 ml/min/1.73m2) has been 
estimated to be between 3.2 to 5.6 % (McCullough 2012). Impaired renal function was thus 
more common among the APSIS patients, and especially among women, as 37 % of them 
had an eCrCl <60 ml/min, compared to 13 % of the male patients. An increased prevalence of 
renal dysfunction has also been found among women in other studies of CV risk (Al Suwaidi 
2002, Best 2002, Anavekar 2004, Go 2004, Weiner 2004), and has usually been related to the 
age difference between men and women in populations with MI and acute coronary 
syndromes. However, there was no age difference between men and women in our study, and 
no difference in renal function between healthy men and women has been found when 
measuring GFR directly by Cr-EDTA clearance (Granerus 1981, Hamilton 2000). There is a 
correction factor in the Cockcroft-Gault formula for gender-related differences, due to the 
lower muscle mass and creatinine production among women, and also in other creatinine 
based formulae commonly used for estimating GFR, such as the Modification of Diet in 
Renal Disease (MDRD) formula (Levey 1999). However, there has been no large evaluation 
of possible differences between men and women in the estimation of GFR by creatinine 
based formulae. Whether the equations are less precise in women needs to be further 
investigated. 
In the APSIS study in patients with stable angina pectoris, the long-term CV prognosis was 
favourable, as the annual incidence of CV death was 1.2 % and that of non-fatal MI was 1.0 
% during a median follow-up of 40 months (Rehnqvist 1996). A long term follow-up after 
the study verified this favourable prognosis (Hjemdahl 2005), and throughout the 9 years of 
observation women had a better prognosis than men, with similar mortality rates as matched 
female reference individuals.  
There is a 10-20 year delay of the onset of coronary artery disease in women compared to 
men (Kannel 1995), and in the APSIS study men had a significantly higher prevalence of 
previous MI or revascularisation than women at inclusion, at the same mean age (59±7 
years). However, among the elderly, CVD is the leading cause of death both in women and 
men (Kannel 1995). The rather low mean age in the APSIS study with no age difference 
between men and women might therefore, to some extent, have contributed to the better 
prognosis among women. Interestingly, the small subgroup of female patients with DM had a 
poor prognosis in the long-term follow up of the APSIS study (Hjemdahl 2005). DM is a 
strong cardiovascular risk factor with accelerated progression of atherosclerosis, and several 
studies report that the gender difference in CV risk is lost in the presence of DM, and that 
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DM increases the CV risk more markedly in women than in men (Kannel 1979, Lee 2000, 
Juutilainen 2004). 
The higher prevalence of impaired renal function among women was a confounder in the 
univariate analyses, because of their better prognosis, and the association between eCrCl and 
the risk for CV death or MI was strengthened by multivariate analysis. In a population with 
older patients, the association between eCrCl and CV risk would probably have been stronger 
due to the higher risk among women. In the HERS study, moderate renal insufficiency was 
associated with an increased risk of suffering CV events among postmenopausal women with 
documented coronary artery disease (Shlipak 2001). 
4.2 PAPER II 
Baseline patient characteristics of the 18 patients in the DM-CKD group and the 21 patients 
in the DM-only group are presented in Table 3. In the DM-CKD group, five patients had 
CKD stage 4 and 13 patients had CKD stage 3. The mean dose of simvastatin was 34±9 mg 
daily in DM only and 30±10mg daily in DM-CKD patients. 
 
Variable DM only 
group 
(n=21)                                          
DM-CKD 
group  
(n=18)
p 
Sex (male/female) 13/8  10/8 0.69 
Age (years) 64 ±7  67±6  0.16 
Smoking (yes/no) 4/17 1/17 0.21 
DM type (type 2/type 1) 13/8 10/8 0.69 
Hypertension (yes/no) 18/3 17/1 0.37 
Plasma creatinine (µmol/L) 73±13 148±65 <0.01 
eGFR (ml/min x 1.73m²)a 87±11  42±13 <0.001 
HbA1c (mmol/mol)b 57±3  59±1  0.99 
Systolic BP (mmHg) 131±13 143±19 0.03  
Diastolic BP (mmHg) 72±9   70±11  0.54 
Total cholesterol (mmol/L) 5.6±1.0 6.0±1.0 0.30 
HDL-cholesterol (mmol/L)  1.3±0.4 1.3±0.4 0.75 
LDL-cholesterol (mmol/L) 3.5±0.8 3.8±1.0 0.31 
Triglycerides (mmol/L) 1.9±1.4 1.9±1.3 0.92 
hsCRP (mg/L)c 1.1 (0.7;3.6) 1.9 (1.3;4.7)  0.68 
Urinary albumin-creatinine ratio (mg/mmol)c 0.8 (0.5;2.1) 10.2 (0.7;32.1) 0.01 
Hemoglobin (g/L) 137±12 126±14 <0.01 
Leukocyte counts (x109/L) 6.5±1.7 6.3±2.1  0.81 
Platelet counts (x109/L) 264±68 245±40  0.32 
Data are means ± SD and p-values from Student´s t-test for independent samples.  
aeGFR estimated with the MDRD formula. bHbA1c = international IFCC (mmol/mol). 
cMedian values (25th and 75th percentiles) and p-values by the Mann–Whitney U-test. 
 
Table 3. Patients characteristics and biochemical analyses at baseline (after the placebo treatment). 
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Influence of CKD on platelet function, platelet-leukocyte aggregation (PLA) 
and inflammatory parameters in DM patients 
At baseline DM-CKD patients had elevated levels of PLAs and sCD40L (Fig 8), as well as of 
plasma elastase (39.2±8.9 vs 31.5±8.9 ng/ml; p=0.01) and VWF (1.4±0.4 vs 1.0±0.4 U/ml; 
p<0.01), compared to DM-only patients: This indicates increased inflammatory activity, 
leukocyte activation and endothelial dysfunction among the DM-CKD patients.  
However, there were no significant group differences regarding platelet P-selectin expression 
(reflecting platelet secretion) or PAC-1 binding (reflecting fibrinogen binding and 
aggregability) in either resting or ADP-, thrombin-, or CRP-18/I stimulated samples (see Fig 
2, Paper II, Appendices). 
Correlations 
PLAs were positively correlated with sCD40L (r=0.33, p=0.04) and VWF (r=0.34, p=0.03) 
and sCD40L was positively correlated with elastase (r=0.39, p=0.01) at baseline among all 
patients. CD40-CD40L interactions have previously been found to increase platelet-leukocyte 
aggregation and leukocyte activation (Lievens 2010) and elevated plasma elastase in DM-
CKD patients might indicate leukocyte activation at least in part induced by CD40-CD40L 
interactions.  
PLAs (r=-0.46, p=<0.01), sCD40L (r=-0.42, p<0.01) and plasma elastase (r=-0.45, p<0.01) 
were all inversely correlated to eGFR at baseline. 
Lipid-lowering treatment reduced PLAs and sCD40L levels in DM-CKD 
Lipid levels did not differ between the two patient groups either before or during LLT (Fig 7) 
(for details see Table 2, Paper IV, Appendices).  
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Figure 7. LDL-cholesterol levels at baseline and after lipid-lowering treatment 
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Combined LLT with simvastatin and ezetimbe significantly reduced PLAs and sCD40L 
levels (Fig 8) as well as P-Neus (p=0.03 by ANOVA; post hoc test p=0.01) among DM-CKD 
patients. The combination treatment significantly reduced LDL cholesterol by 63% in DM-
only and 66% in DM-CKD patients (p<0.001 for both). Simvastatin alone, which lowered 
LDL cholesterol by 47% in DM-only and by 48% in DM-CKD patients (p<0.001 for both), 
reduced P-Neus in DM-CKD patients (p=0.03 by ANOVA; post hoc test p=0.02), but only 
tended to reduce total PLAs and sCD40L. In DM-only patients there were no significant 
effects of either LLT regimen on PLAs or sCD40L. No carry-over effect between treatment 
periods was found for any variable, and HbA1c levels were not affected by LLT in either 
patient group (data not shown). 
 
Discussion 
CKD and/or the presence of albuminuria are associated with increased inflammatory activity 
and endothelial dysfunction, which may explain the elevations of PLAs, sCD40L, VWF and 
plasma elastase in the DM-CKD group. Elevated levels of sCD40L and VWF have 
previously been found in patients with CKD, compared to healthy controls (Schwabe 1999) 
 
Figure 8. Platelet-leukocyte 
aggregates (PLA%) in the total 
leukocyte population in 
unstimulated samples (panel A) 
and plasma levels of sCD40L 
(panel B) in the DM-CKD (□ 
dotted line) and DM only (• 
solid line) groups. 
Measurements were at baseline 
(placebo) and during treatment 
with simvastatin (Sim), and 
simvastatin+ezetimie 
(Sim+eze). P-values are post 
hoc test in the ANOVA. Group 
differences by repeated 
measures ANOVA are shown 
in the figure. Data are means ± 
SEM.  
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as well as in diabetic nephropathy compared to DM patients with normoalbuminuria (Lajer 
2010). 
Intensive LLT with simvastatin and ezetimibe reduced PLA formation and sCD40L in the 
DM-CKD group whereas simvastatin alone only tended to reduce these parameters. Both 
platelet-leukocyte interactions and the CD40-CD40L system form links between platelets and 
inflammation. Activated platelets are the main source of sCD40L in plasma (Antoniades 
2009), and CD40-CD40L interactions promote PLA formation (Lievens 2010). Since there 
were no other signs of reduced platelet activation (i.e., P-selectin expression or PAC-1 
binding), it might be suggested that the reduced levels of sCD40L during combination 
treatment were involved in the reduction of PLA formation among our DM-CKD patients. 
Interestingly, neither sCD40L nor PLAs decreased with increasing LLT intensity in the DM-
only group. 
4.3 PAPER III 
In this extended analysis of study II we found elevated levels of IFNγ, TNFα, MCP-1 and 
sVCAM-1 among DM-CKD compared to DM-only patients (see Table 2, Paper III, 
Appendices). These parameters were all inversely correlated to eGFR (r=-0.53, r=-0.53, r=-
0.43, r=-0.64, respectively; p<0.01 for all). 
Effects of lipid-lowering treatment 
In DM-CKD patients, simvastatin alone reduced the plasma levels of MCP-1 and IFNγ, and 
combined LLT with simvastatin and ezetimibe decreased them further (Fig 9). In the DM-
only group, there were no significant effects of either LLT regimen on MCP-1 or IFNγ. 
Differences between the groups at baseline thus disappeared during treatment. Combined 
LLT reduced sVCAM-1 levels overall, with a significant effect in the DM-only group, and 
the difference between the groups thus remained during LLT (p=0.81 for interaction term in 
the ANOVA).  
 
 
 
 
Figure 9. Plasma levels of MCP-1 (A) and INFγ (B) in the DM-CKD group (dotted 
line) and in DM-only groups (solid line). Measurements were at baseline (placebo) and 
during treatment with simvastatin (Sim), and simvastatin+ezetimie (Sim+eze). P-values 
are group differences at baseline (Student´s t-test). P-values are post hoc test in the 
ANOVA. Data are means ± SEM. 
A B 
 26 
Discussion 
Since CKD and diabetic nephropathy are associated with increased inflammatory activity, the 
elevation of inflammatory parameters in our DM-CKD patients was not a surprising finding, 
as discussed above. IFNγ and TNFα are powerful proinflammatory cytokines with key roles 
in the development and progression of atherosclerosis (McLaren 2009, Ait-Oufella 2011), 
and the chemokine MCP-1 is important for the infiltration of monocytes into early 
atherosclerotic lesions. Oxidized LDL cholesterol, but not native LDL cholesterol, induces 
MCP-1 production in endothelial and smooth-muscle cells and may be a molecular link 
between oxidized lipoproteins and foam cell formation in the vessel wall (Charo 2004). 
MCP-1 may also activate tissue factor and thus contribute to thrombin generation and 
thrombus formation (Charo 2004). Thus, elevations of IFNγ, TNFα and MCP-1 among DM-
patients with CDK may be of importance for their increased cardiovascular risk. MCP-1 may 
also contribute to the pathogenesis of diabetic nephropathy by facilitating the migration of 
monocytes and macrophages into the kidney (Galkina 2006).  
Several studies have shown reduced levels of proinflammatory mediators, including IFNγ and 
MCP-1, during statin treatment (Bonetti 2003, Schonbeck 2004), in agreement with our 
results. Antiinflammatory effects of statin treatment are believed to be of importance for the 
reduction of atherosclerotic complications (Hansson 2005) due to a combination of LDL-
related effects and pleiotropic anti-inflammatory effects. Reduced levels of MCP-1 and IFNγ 
during simvastatin treatment might beneficial with regard to the progression of both 
atherosclerosis and diabetic nephropathy in patients with DM and concurrent CKD 
4.4 PAPER IV 
Elevated levels of circulating microparticles (MPs) in DM-CKD patients 
The total counts of all types of MPs studied (total PS+MPs, PMPs, MMPs, EMPs) were 
elevated in DM patients with CKD stages 3-4 compared to DM-only patients at baseline. The 
expressions of P-selectin, CD40L and TF on PMPs, as well as of TF on EMPs were also 
higher in DM-CKD compared to DM-only patients (Fig 10) (Table 4). 
Lipid-lowering treatment reduces procoagulant MPs 
In DM patients with CKD stages 3-4, LLT with simvastatin alone significantly reduced the 
counts of total procoagulant PS+MPs, MMPs and PMPs, and the expression of P-selectin, 
CD40L and TF on PMPs as well as of TF on MMPs, compared to placebo (for statistics see 
Table 4). Combination treatment with simvastatin and ezetimibe had no further effect. 
Addition of ezetimibe, however, reduced the expression of TF on EMPs in the DM-CKD 
group. In DM-only patients simvastatin reduced the expression of P-selectin, TF and CD40L 
on PMPs and of TF on MMPs, compared to placebo. Combination treatment was required to 
achieve reductions of all PMPs, MMPs and TF expression of EMPs in the DM-only group. 
The difference between DM-CKD and DM-only seen at baseline disappeared with 
simvastatin treatment (Fig 10) (Table 4). 
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DM-CKD patients thus responded better to simvastatin treatment than DM-only patients, 
with no further effect of adding ezetimbe (Fig 10). DM-only patients demonstrated a more 
dose-response like pattern for LDL-lowering, since combination treatment resulted in a trend 
towards further decreases of activation markers on PMPs and MMPs and was required to 
significantly reduce the total counts of PMPs and MMPs in this patient group (Fig 10). 
Changes of lipid levels and MP formation were not correlated in either patient group. 
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Figure 10. Levels of all PMPs (A), P-selectin expressing PMPs (B), TF expressing PMPs (C), 
CD40L expressing PMPs (D), all MMPs (E) and TF expressing MMPs (F) in the DM-CKD 
(dotted line) and DM-only (solid line) groups. Measurements were at baseline (placebo) and 
during treatment with simvastatin (Sim), and simvastatin+ezetimie (Sim+eze). P-values are 
group differences at baseline (Student´s t-test). P-values are post hoc test in the ANOVA. Data 
are means ± SEM. 
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Table 4. Levels of microparticles at baseline (after the placebo run-in) and after lipid-lowering 
treatment. 
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Elevations of EMPs with lipid-lowering treatment  
Simvastatin significantly elevated the levels of EMPs expressing VE-cadherin (PS+CD144+) 
in both patient groups, compared to placebo (Fig 11). Combination treatment with 
simvastatin and ezetimibe did not elevate the levels of VE-cadherin+ EMPs any further than 
did simvastatin alone in either of the patient groups. Simvastatin alone elevated EMPs 
expressing E-selectin (PS+CD62E+) in DM-only patients compared to placebo (post-hoc test 
p<0.001) (Fig 11). The expression of TF on CD62+ EMPs (CD62E+CD142+) was reduced 
during combination treatment in both patient groups (Table 4).  
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Discussion 
MPs are released from various cells upon activation and/or apoptosis and appear to both 
contribute to, and a consequence of inflammation (Burger 2013). Increased inflammatory 
activity in the DM-CKD group was thus most likely of importance for the difference in MP 
formation between DM-CKD and DM-only patients. Circulating PMPs are the most abundant 
microparticles in the circulation, and seem to be markers of inflammation, platelet activation 
and hypercoagulability (Burger 2013). Like platelets, MPs have procoagulant activity through 
the exposure of negatively charged PS on the surface which allows coagulation factors to 
bind and thereby enable the formation of tenase and prothrombinase complexes and the 
Figure 11. Levels of CD144+ (VE-cadherin) EMPs (A), CD62E+ (E-selectin) EMPs (B) and 
CD142+ (TF) CD62+ EMPs (C) in the DM-CKD (dotted line) and DM-only (solid line) 
groups.  Measurements were at baseline (placebo) and during treatment with simvastatin 
(Sim), and simvastatin+ezetimie (Sim+eze). P-values are group differences at baseline 
(Student´s t-test). P-values are post hoc test in the ANOVA. Data are means ± SEM. 
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promotion of thrombin generation (Burger 2013). TF expressed on MPs may also contribute 
(Owens 2011).  
Reduced levels of PMPs as well as decreased expression of procoagulant proteins on PMPs 
during simvastatin treatment suggest that such treatment reduces platelet activation and 
hypercoagulability. The mechanisms through which statin treatment reduced the formation of 
PMPs need further clarification.  
Statins are also suggested to have anticoagulant effects through reductions of TF via both 
lipid- and non-lipid dependent pathways (Owens 2014). MMPs are considered to be the main 
MP-related source of TF which may be transferred to platelets and PMPs from monocytes 
(Owens 2011, Osterud 2012). The expression of TF on MPs has been much debated, 
especially whether or not it is active (Owens 2011). Recent studies suggest that TF may 
contribute to the procoagulant effects of MPs (Owens 2014), and the markedly reduced 
expression of TF on MMPs and PMPs during simvastatin treatment in our study indicates a 
less procoagulant milieu. However, as shown by our coworkers, the main procoagulant 
effects of MPs are most likely an interaction between PS expression and TF expression  
(Mobarrez 2011). As TF is dependent on PS to activate FVII, one can speculate that TF 
expression on MPs can help initiate the coagulation, and later the exposed PS on MPs can 
maintain or even further promote coagulation.  
As discussed above, the CD40-CD40L system promotes proinflammatory and prothrombotic 
alterations in atherothrombosis. Statins have been found to reduce the plasma levels of 
sCD40L and the CD40L expression of human endothelial and smooth muscle cells 
(Antoniades 2009). The reduced expression of CD40L on PMPs by simvastatin treatment in 
both patients groups in our study, may contribute to beneficial reductions of inflammatory 
activity and hypercoagulability.  
EMP release is proposed to reflect endothelial cell activation and dysfunction (Burger 2013). 
The current findings of elevated EMPs in plasma during simvastatin treatment are surprising 
since improvement of endothelial function is thought to be one of the major pleiotropic 
effects of statins (Bonetti 2003). However, the present findings are in line with previous 
results from our coworkers showing an increased release of EMPs during treatment with 
atorvastatin (80 mg/day) in patients with peripheral arterial occlusive disease (Mobarrez 
2012). In patients with type-1 DM, high-dose atorvastatin treatment caused impaired 
endothelium-dependent function of microvessels and a tendency toward elevated levels of 
EMPs (Tehrani 2013). In addition, the EMP release from human umbilical endothelial cells 
has been shown to be increased by simvastatin in vitro (Diamant 2008). Some in vitro studies 
have suggested that statins may contribute to apoptosis by inducing expression of the 
proapoptotic enzymes caspase-3 and -9, and by interfering with Ras prenylation (Schonbeck 
2004). However, further research is needed to clarify how statins influence EMP release and, 
most importantly, the possible clinical consequences of this.  
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5 GENERAL DISCUSSION 
5.1 RENAL FUNCTION AS A PROGNOSTIC PREDICTOR 
The burden of CV mortality and morbidity is a growing, worldwide health problem. CKD 
(i.e, eGFR <60ml/min/1.73m2) is now considered to be an independent predictor of all-cause 
and CV mortality in both the general population and in populations with increased risk for 
CKD, defined as a history of hypertension, diabetes, or cardiovascular disease (Chronic 
Kidney Disease Prognosis 2010, van der Velde 2011). As reported in Paper I, we found that 
impaired renal function carried independent prognostic information regarding the risk of 
suffering CV death or nonfatal MI in patients with stable angina pectoris. The prognostic 
impact was graded and the risk of CV death or non-fatal MI was doubled at eCrCl <60 ml 
/min compared to eCrCL ≥90ml/min. This is in line with data from large cohort studies in 
which patients with moderately reduced renal function (eGFR 30-59 ml/min1.73m2) were 
found to have a doubled risk, and patients with severely decrease renal function (eGFR 15-29 
ml/min1.73m2) had a trippled risk for cardiovascular mortality compared to individuals with 
normal renal function. There seems to be a threshold for increased CV risk around eGFR 60 
ml/min/1.73m2, and below this threshold there is an exponential increase in risk as eGFR 
declines (Chronic Kidney Disease Prognosis 2010, van der Velde 2011). 
Thus, patients with CKD should be considered to belong to one of the highest-risk groups for 
CV events and disease, and considerable attention should be paid to risk factor management 
and CV risk reduction therapies in these patients. However, despite the increasing attention to 
the close relationship between CKD and CV risk during recent years, studies repeatedly point 
out that the CVD risk in patients with impaired renal function is poorly recognised and often 
undertreated. Patients with CKD and CVD are not receiving adequate treatment with aspirin, 
beta-blockers, ACE-inhibitors and statins according to current guidelines to the same extent 
as patients without CKD (Tonelli 2001, Wright 2002, Szummer 2010). They are also less 
frequently treated with anticoagulants and revascularization in non-ST-elevation MI or 
reperfusion therapy in ST-elevation MI (Wright 2002, Szummer 2010). Thus, patients with 
reduced renal function should be identified early, and there is a considerable need for 
improved risk factor management and improved CVD risk reduction therapy. In the 
development of new clinical guidelines for CV treatment and prevention, patients with CKD 
should receive special attention.  
5.2 SIGNS OF INCREASED INFLAMMATION AND HYPERCOAGULABILITY IN 
DM-CKD PATIENTS 
The increased CV risk in patients with CKD is in part due to the high prevalence of 
traditional risk factors such as diabetes and hypertension but the strong association between 
impaired renal function and CV risk cannot only be explained by this. Thus, ”non-traditional” 
risk factors seem to play an important role in the excessive CV risk in patients with CKD. 
Chronic inflammatory activation is considered to be an important such non-traditional risk 
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factor. Inflammation is highly involved in both atherosclerosis and thrombosis (Ross 1999) 
and is common among patients with CKD. 
In our study, reported in Papers II-IV, we found signs of increased inflammatory activity with 
increased PLA formation and MP formation, as well as elevated levels of proinflammatory 
cytokines and sCD40L, in DM patients with concurrent CKD compared to DM patients with 
normal renal function. Similar to CKD, DM is also associated with increased inflammatory 
activity, as well as endothelial dysfunction and oxidative stress, factors which are considered 
to be associated with the high CV risk in these patients (Goldberg 2009). Furthermore, both 
DM and CKD are considered to be prothrombotic states with major hemostatic disturbances 
(Hess 2011, Lutz 2014). Thus, DM and CKD share many features that act as risk factors for 
CVD, and when DM and CKD are concurrent, these risk factors may amplify each other and 
result in an excessive risk of suffering CV events. Thus, our findings with signs of increased 
inflammatory activity and endothelial dysfunction in DM patients with concurrent CKD 
stages 3-4, compared to DM patients with normal GFR, were expected and are probably of 
importance for the increased CV risk in these patients.  
There are many links between inflammation, platelets and coagulation, and our observations 
of elevated levels of PMPs and increased expression of P-selectin, CD40L and TF on PMPs 
in Paper IV may, together with the increased PLA formation and sCD40 levels reported in 
Paper II, indicate not only increased inflammatory activity but also suggest that there is a 
state of increased platelet activation and hypercoagulability in the current DM-CKD patients.  
Whether CKD is associated with increased platelet activation is controversial. Impaired renal 
function has most commonly been associated with platelet dysfunction causing reduced 
aggregability with an increased risk of bleeding (Lutz 2014). However, there is an increasing 
number of studies showing hyperreactive platelets or increased platelet activation in patients 
with CDK (Thijs 2008,Landray 2004, Woo 2011, Gremmel 2013, Yagmur 2013), and Baber 
et al found that platelet reactivity in patients undergoing percutaneous coronary intervention 
was higher among patients with both DM and CKD compared to those with one condition 
alone (Baber 2013). In paper II we found no signs of increased platelet activity as evaluated 
by single platelet P-selectin expression or fibrinogen receptor binding in DM-CKD compared 
with DM-only patients. It is worth noting that the patients in our study had no history of 
previous MI or stroke and that they were well-controlled regarding blood pressure, lipid-
levels and HbA1c etc., with no differences between the two patient groups. This relatively 
low risk profile at baseline might be associated with less activated platelets and therefore a 
limited possibility of detecting group differences. However, platelet activity is a complex 
issue and different parameters reflecting it may be differentially altered by disease states and 
treatments. Measuring PLA formation and PMP release illustrate other aspects of platelet 
activity than activity markers on single platelets, and these measures suggested that platelet 
activity indeed was increased in our DM-CKD patients.  
We found no differences between men and women in any of the evaluated parameters in 
Papers II-IV, but the groups were too small to reveal limited gender differences. The 
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association between CKD and CV mortality has been found to be at least as strong in women 
as in men and the relationship between reduced eGFR and increased mortality is steeper in 
women than in men (Nitsch 2013). Data concerning gender differences in inflammatory 
activity and hypercoagulability in CKD are sparse, and further research in this area would be 
of interest. 
5.3 EFFECTS OF LIPID-LOWERING TREATMENT 
We found markedly reduced levels PMPs and MMPs and their expression of protrombotic 
markers and reduced levels of IFNγ and MCP-1 with simvastatin treatment, and reduced PLA 
formation and sCD40L levels with combination LLT with simvastatin and ezetimibe in DM 
patients with CKD. These findings suggest reduced inflammatory activity, as well as reduced 
platelet activation and less hypercoagulability, which might contribute to the beneficial 
effects of LLT on atherothrombotic complications in DM patients with concurrent CKD. The 
exact mechanisms responsible for the antithrombotic properties of statin treatment are still 
not fully understood. Reductions of lipids and lipoprotein levels are most likely important but 
so-called pleiotropic effects may well contribute.  
Statins have been shown to interfere with CD40-CD40L interactions at several levels which 
seem to be both lipid-dependent and -independent (Schonbeck 2004), and may thereby 
influence platelet activity and hypercoagulability (Antoniades 2009). Activated platelets are 
the main source of sCD40L (Antoniades 2009), and we found reduced levels of sCD40L with 
combined LLT as well as reduced CD40L expression on PMPs with simvastatin treatment in 
our DM-CKD patients. As discussed above, the reduced levels of sCD40L during 
combination treatment might have been involved in the reduction of PLA formation seen 
among our DM-CKD patients.  
Circulating microparticles seem to have a strong association with endothelial damage, platelet 
activation and hypercoagulability and are emerging as interesting players in the complex 
process of atherosclerosis and atherothrombotic complications (Shantsila 2010). There is 
growing interest in the possibility to modulate the levels of MPs and their expression of 
prothrombotic markers with pharmacological agents, such as statins. Previous studies have 
suggested that statin treatment may decrease MP production (Nomura 2004, Sommeijer 
2005), and our coworkers have previously found that atorvastatin treatment reduced the 
expression of TF, P-selectin and GPIIIa on PMPs in patients with peripheral arterial occlusive 
disease (Mobarrez 2011), and in patients with type-1 diabetes (Tehrani 2010). The study 
presented in paper IV is, to our knowledge, the first to investigate statin associated effects on 
MP formation in patients with CKD. The results of this study suggest that MPs may be 
involved in the hypercoagulable state in CKD and that influences of LLT on MP production 
can lead to a less procoagulant milieu. However, surprisingly we found elevated levels of 
EMPs in plasma during simvastatin treatment. Thus, different MP subpopulations may 
behave differently during statin treatment, and further research is needed to clarify these 
mechanisms and their possible importance. 
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5.4 THE INFLUENCE OF CKD WAS COUNTERACTED BY LIPID-LOWERING 
TREATMENT 
Interestingly, the differences between DM-CKD and DM-only patients at baseline regarding 
PLA-formation, inflammatory parameters and procoagulant PMPs and MMPs, were 
counteracted by LLT. PLA formation and sCD40L levels were reduced with simvastatin + 
ezetimibe, and IFNγ and MCP-1 were reduced with simvastatin alone in DM-CKD patients 
but not in DM-only patients. The effect of simvastatin on PMP levels, as well as on the 
expression of P-selectin, CD40L and TF on PMPs was more prominent in DM-CKD patients 
than in DM-only patients. Thus DM-only and DM-CKD patients responded differently to 
LLT despite similar LDL reductions and similar lipid-levels at baseline. Why these responses 
to LLT were enhanced when CKD was present is not known, but the effects may be related to 
beneficial effects on the increased inflammatory activity among CKD patients.  
Statins effectively decrease blood lipid levels by inhibiting the enzyme HMG-CoA reductase 
and thereby cholesterol synthesis, but they may also influence inflammatory activity and 
atherothrombotic mechanisms independently of their lipid-lowering effect, mainly due to 
inhibition of the synthesis of isoprenoid intermediates of the mevalonate pathway and thereby 
altered protein prenylation, as discussed before. However, since hyperlipidemia itself is 
associated with increased inflammatory activity (Siasos 2011), and oxidized LDL particles 
play an important role in the triggering of inflammation in atherosclerosis (Hansson 2005), 
the reduction of LDL most likely influences inflammatory activity in concert with possible 
pleiotropic effects of statin treatment. Oxidized LDL particles may also, apart from activating 
endothelial cells and inducing an inflammatory response in the arterial wall, be directly 
procoagulant by supporting thrombin generation on their PS expressing, negatively charged 
surfaces (Griffin 2001). The exact mechanisms through which statins reduce cardiovascular 
complications are still uncertain, and a most interesting question is to what extent their effects 
are related to the LDL reduction or to other pleiotropic effects.  
In Papers II-IV we studied the effects of simvastatin alone or with ezetimibe and we could 
hence evaluate whether additional LDL reduction with the same statin dose would provide 
additional effects. Since combination treatment with simvastatin and ezetimibe was required 
to achieve significant reductions of PLA formation and sCD40L, with only a trend towards 
decreased levels with simvastatin alone in DM-CKD patients, it is difficult to invoke 
pleiotropic effects of statin treatment as the primary mechanisms behind these findings. 
Furthermore, the reductions of IFNγ and MCP-1 were significant with simvastatin alone, but 
increased when ezetimibe was added. Since pleiotropic effects of ezetimibe are uncertain 
(Kalogirou 2010) the additional 18% lowering of LDL cholesterol achieved with combination 
treatment might explain these further reductions. This is in line with a meta-analysis by 
Kinlay et al., which included 23 studies with 57 groups treated with different LLT regimens 
and concluded that most of the anti-inflammatory effect of LLT is related to the magnitude of 
change in LDL (Kinlay 2007). However, the meta-analysis was dominated by statin studies 
and it is difficult to separate directly LDL-related effects from pleiotropic effects. A most 
interesting study for the future would be to compare the antiinflammatory and antithrombotic 
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effects of statins with those of new lipid-lowering drugs, such as the proprotein convertase 
subtilisin/kexin type 9 (PCSK9) inhibitors which causes marked reductions of LDL (Koren 
2014), in order to distinguish between LDL related and possibly LDL independent pleiotropic 
effects.  
5.5 LIPID-LOWERING TREATMENT IN CKD AND CLINICAL OUTCOMES 
The Study of Heart and Renal Protection (SHARP) was the first trial specifically powered to 
investigate atherosclerotic outcomes in non-dialysis CKD patients. It showed a 17% 
reduction of major atherosclerotic events with combined simvastatin and ezetimibe treatment 
compared to placebo in patients with CKD and no prior MI or coronary revascularization (i.e, 
primary prevention) (Baigent 2011). Unfortunately, the trial lacked a group treated with 
simvastatin only but a recent large meta-analysis including data from 51099 patients with 
CKD (including SHARP) concluded that statin treatment reduces cardiovascular mortality 
and cardiovascular events in CKD patients who are not receiving dialysis (Palmer 2012). The 
proportional decreases in major cardiovascular and mortality outcomes in this meta-analysis 
were similar to or larger than those observed in broader populations with established CVD 
(Baigent 2005). There was also an additional analysis after excluding SHARP which found 
treatment effects for statins alone to be similar to those of combined therapy with 
statin+ezetimibe (Palmer 2012). Thus, statin treatment has beneficial effects on 
cardiovascular morbidity and mortality in patients with CKD similar to other high-risk 
populations, as DM patients, but the addition of ezetimbe has not yet been shown to improve 
clinical outcomes in any of these populations. 
The Kidney Disease: Improving Global Outcomes (KDIGO) organization has recently 
developed clinical practice guidelines on lipid management in CKD (Tonelli 2014). These 
guidelines are mainly based on the results of the SHARP study and post hoc analyses of trial 
from the general population focusing on participants with CKD. A key recommendation in 
these new guidelines is to use statin or statin/ezetimibe treatment for primary prevention, 
regardless of blood cholesterol levels, in patients aged ≥50 years with eGFR <60 
ml/min/1.73m2 who are not treated with dialysis. Furthermore, statins are recommended for 
all DM patients with non-dialysis-dependent CKD. These guidelines will likely increase the 
use of statins in CKD patients worldwide and hopefully contribute to reduced CV mortality 
and morbidity in the future. The findings in our study, suggesting beneficial effects of LLT 
on inflammatory activity and hypercoagulability in DM patients with CKD stages 3-4, could 
be of importance with regard to CV risk reduction in these high-risk patients. 
5.6 LIMITATIONS 
The major limitation of our DM-CKD study presented in Papers II-IV is the small number of 
patients which limited the ability to reveal modest differences in treatment effects. Another 
possible limitation is the lack of a control group without DM. However, we did not study 
patients with CKD only or healthy individuals since the influence of DM has been studied 
previously and our aim was to elucidate the influence of CKD in DM. We included patients 
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with both type 1 and type 2 DM. The lesions underlying renal dysfunction in type 1 and type 
1 DM may differ, but the present study focused on prothrombotic mechanisms in DM, 
irrespective of its type. We found no differences between type 1 and type 2 DM patients in 
any of the evaluated parameters in Papers II-IV, but the groups were small which limited the 
ability to reveal differences depending on the type of DM. 
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6 FUTURE PERSPECTIVES  
Based on the present findings it would be of interest to: 
§ Further characterize procoagulant mechanisms in different CKD-stages with a focus 
on the connection between inflammation, platelet function and MPs. 
 
§ Compare the antiinflammatory and antithrombotic effects of statins with those of new 
lipid-lowering drugs, such as the proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibitors, in order to distinguish between LDL related and possibly LDL 
independent pleiotropic effects of statin treatment. 
 
§ Further evaluate MP formation in patients with CKD without DM and possible 
relationships to CDK stages and types of underlying renal disease. 
 
§ Evaluate in larger trials whether MP measurements could be used for prognostic 
purposes and risk assessment of patients with CKD. 
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7 SUMMARY AND CONCLUSIONS  
The following conclusions can be drawn from this work: 
§ Impaired renal function provided independent prognostic information regarding the 
risk of suffering cardiovascular death or MI in patients with chronic stable angina 
pectoris, in agreement with findings in patients with other categories of coronary 
artery disease as well as in the normal population. 
§ The prognostic impact was graded and patients with eCrCl <60 ml/min had a doubled 
risk of suffering CV death or MI, compared to patients with eCrCl ≥90 ml/min. 
§ Patients with DM and concurrent CKD stages 3-4 (eGFR 15-59 ml/min/1.73m2) had 
signs of increased inflammatory activity, platelet activation and hypercoagulability 
compared to DM patients with normal eGFR. This may be of importance for their 
increased cardiovascular risk. 
§ Lipid-lowering treatment (LLT) with simvastatin alone markedly reduced the levels 
of prothrombotic microparticles derived from platelets and monocytes and their 
expression of activation markers, and reduced the plasma levels of IFNγ and MCP-1 
in DM patients with CKD stages 3-4. 
§ Combination LLT with simvastatin and ezetimibe reduced platelet-leukocyte 
aggregation and sCD40L levels in DM patients with CKD stages 3-4. 
§ These findings suggest reduced inflammatory activity, as well as reduced platelet 
activation and less hypercoagulability, which might contribute to the beneficial effects 
of LLT on atherothrombotic complications in DM patients with concurrent CKD. 
§ Influences of CKD on markers associated with increased inflammation and platelet 
activation were counteracted by LLT in patients with DM. 
§ LLT elevated the levels of microparticles derived from endothelial cells, which could 
imply deterioration of some aspects of endothelial function. Further research is 
needed to clarify these mechanisms and their possible importance. 
§ Neither the LDL lowering effect alone nor possible pleiotropic effect of statin 
treatment could independently explain the findings in this work. Thus, LDL-
dependent and -independent mechanisms likely act in concert with regard to anti-
inflammatory and anti-thrombotic effects of LLT.  
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8 SVENSK SAMMANFATTNING 
Njurarna har en livsviktig funktion när det gäller att rena blodet från restprodukter som 
kroppen inte behöver samt att avlägsna överflödigt vatten. Njursvikt innebär att njurarna av 
någon orsak inte klarar av detta, och skadliga ämnen stannar kvar i kroppen. Kronisk 
njursvikt innebär att njurarna långsamt blir sämre, ofta under flera år. Diabetes mellitus 
(sockersjuka) är en av de vanligaste orsakerna till kronisk njursvikt, till stor del beroende på 
den snabba ökningen av typ 2 diabetes och fetma världen över. Personer med diabetes eller 
kronisk njursvikt löper en mycket hög risk att utveckla hjärt-kärlsjukdom (som t.ex. 
hjärtinfarkt eller stroke) och risken är ännu högre om man har båda tillstånden samtidigt. 
Hjärt-kärlsjukdom är den vanligaste dödsorsaken hos personer med kronisk njursvikt och en 
person med måttlig kronisk njursvikt har dubbelt så stor risk att dö i hjärt-kärlsjukdom 
jämfört med en person med normal njurfunktion.  
Både diabetiker och personer med kronisk njursvikt har en förändrad/störd hemostas 
(kroppens förmåga att bilda och bryta ner blodproppar) och aktiverade ”kladdiga” blodplättar 
(trombocyter). Detta ger en ökad benägenhet att koagulera (levra) blodet och därmed en ökad 
risk att bilda blodproppar. Personer med diabetes och njursvikt har också tecken på kronisk 
inflammation, vilket också bidrar till den störda balansen i hemostasen, till aktivering av 
blodplättarna samt till ökad åderförkalkning i blodkärlen.  
Behandling med en grupp av läkemedel som sänker blodfetterna, så kallade statiner, minskar 
risken för hjärt-kärlsjuklighet hos personer både med diabetes och kronisk njursvikt.  
Statinerna hämmar ett enzym i kolesterolsyntesen i levern, med minskad 
kolesterolproduktion som följd. Statinerna har också visat sig ha effekter som inte enbart kan 
förklaras av den blodfettsänkande effekten, som t.ex. att minska inflammatorisk aktivitet och 
minska benägenheten för blodkoagulation. Dessa effekter spelar sannolikt en viktig roll, 
tillsammans med själva blodfettsänkningen, för statinernas skyddande effekter.  
Ezetimibe är en annan typ av blodfettsänkande läkemedel som verkar genom att hämma 
upptaget av kolesterol från maten. Vid kombinationsbehandling med ezetimibe och en statin 
uppnår man en kraftigare blodfettssänkning än med enbart en statin. 
Syftet med den här avhandlingen har varit att närmare undersöka effekten av 
blodfettsänkande behandling med statinen simvastatin enbart eller i kombination med 
ezetimibe hos patienter med diabetes, med eller utan kronisk njursvikt. Vi ville studera hur 
blodplättar, andra faktorer i hemostasen samt inflammatorisk aktivitet påverkas av 
statinbehandling. Vi ville också studera om ytterligare kolesterolsänkning genom tillägg av 
ezetimibe till simvastatin påverkar dessa parametrar och därmed risken för blodpropp. I 
denna avhandling har vi också studerat om nedsatt njurfunktion har någon prognostisk 
betydelse hos patienter med kärlkramp (angina pectoris). 
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Med hjälp av en ekvation kan njurfunktionen skattas utgående från mängden av ett ämne i 
kroppen som heter kreatinin. Vid njursvikt ansamlas kreatinin i ökande mängd i blodet.  
I delstudie 1 skattade vi njurfunktionen på detta sätt hos 808 patienter med kärlkramp som 
alla deltog i en studie som utvärderade risken för hjärtinfarkt och hjärt-kärl död vid 
behandling med två olika typer av läkemedel. Vi fann att patienter med kärlkramp relativt 
ofta har måttligt nedsatt njurfunktion, framför allt kvinnor. Vi fann också att nedsatt 
njurfunktion har prognostisk betydelse för risken att drabbas av hjärt-kärl död eller 
hjärtinfarkt hos patienter med kärlkramp, vilket betyder att ju sämre njurfunktionen är desto 
större är risken att drabbas. I denna studie hade patienter med måttligt nedsatt njurfunktion 
dubbelt så stor risk att drabbas av hjärt-kärl död som patienter med normal njurfunktion, och 
risken fortsatte att öka hos de med sämre njurfunktion. Detta samband mellan nedsatt 
njurfunktion och risken för hjärt-kärlsjuklighet och död är även påvisat i många andra studier. 
Patienter med kronisk njursvikt är således en högriskgrupp. Det är mycket viktigt att 
upptäcka kronisk njursvikt tidigt för att kunna vidta åtgärder som minskar risken för att 
njurarna försämras ytterligare och minska risken hjärt-kärlsjukdom, t.ex. sänka blodtrycket, 
sluta röka, gå ner i vikt eller behandla höga blodfetter. 
I den studie som ligger till grund för resultaten i delstudie II-IV inkluderade vi 18 
diabetespatienter med kronisk njursvikt stadium 3-4 (måttlig till grav njursvikt) samt 21 
diabetespatienter med normal njurfunktion. Efter en 6 veckor lång inledande period med 
”sockerpiller” (placebo) behandlades patienterna med simvastatin enbart i en 8-10 veckors 
lång period samt därefter med simvastatin+ezetimibe i en 8-10 veckors lång period. Efter 
varje behandlingsperiod undersöktes funktionen av så kallade mikropartiklar, blodplättar, vita 
blodkroppar, samt inflammations markörer. Mikropartiklar är mycket små membranpartiklar 
som avknoppas från ett flertal olika celler såsom blodplättar, vita blodkroppar och 
endotelceller (celler som täcker blodkärlens insida), vid retning eller celldöd. Mikropartiklar 
verkar ha en viktig betydelse för bland annat blodproppsbildning och inflammation. Vi fann 
att diabetespatienter med kronisk njursvikt hade tecken på ökad inflammatorisk aktivitet, 
ökad bildning av aggregat av blodplättar och vita blodkroppar (PLA) samt ökad mängd 
mikropartiklar från blodplättar, vita blodkroppar och kärlvägg jämfört diabetespatienter med 
normal njurfunktion. Detta kan vara av betydelse för den ökade hjärt-kärl risken hos dessa 
patienter. 
Vi fann att blodfettsänkande behandling med enbart simvastatin minskade nivåerna av 
mikropartiklar från blodplättar och vita blodkroppar. Simvastatin minskade också nivåerna av 
två specifika inflammatoriska molekyler (IFNγ och MCP-1) och behandling med simvastatin 
+ ezetimibe minskade PLA-bildning hos patienterna med njursvikt men inte hos 
diabetespatienterna med normal njurfunktion. Dessa resultat talar för att den blodfettsänkande 
behandlingen bidrog till minskad inflammatorisk aktivitet, minskad aktivering av blodplättar 
samt minskad tendens till blodkoagulering, vilket kan vara av betydelse för att minska risken 
för hjärt-kärl sjukdom hos diabetespatienter med kronisk njursvikt. 
 
 42 
9 ACKNOWLEDGEMENTS 
There are many people to whom I wish to express my sincere gratitude for helping me in 
making this thesis possible, especially all the patients participating in the clinical studies 
included in this work. In particular I wish to thank: 
Paul Hjemdahl, my main supervisor, for support and guidance during all these years and for 
introducing me to scientific thinking. In particular I am thankful for all you have taught me 
about writing. You are an inspiring research and writing model, with your profound scientific 
knowledge and clear thinking. You have a wonderful way of improving any text, making it 
clear, elegant, and precise.  
Stefan Jacobson, my co-supervisor, for all your support, enthusiasm and encouragement, 
and for being such an inspiring person and researcher. Thank you for sharing all your 
optimism, energy and great knowledge, and for all the laughs any conversation with you 
always contains. 
Per-Eric Lins, my co-supervisor, for sharing your great scientific ideas and for always being 
so encouraging, friendly and supportive.  
Jonas Berglund, my former co-supervisor and former boss, first of all for employing me at 
the Department of Nephrology and also for being one of the initiators of this project. 
Fariborz Mobarrez, co-author, for all your help and assistance, for introducing me into the 
fields of microparticles, and for being such a nice person. Also, Håkan Wallén, co-author, 
for being so encouraging and supportive, always taking time to answer my questions and for 
interesting discussions. 
Lennart Forslund, co-author, for helping me with my first stumbling steps into statistics and 
writing a scientific paper. Also, Nina Rehnqvist and Richard Farndale, co-authors, for 
valuable constructive criticism of the manuscript to Paper I. Also Per Näsman, co-author, for 
invaluable statistical support and advice. 
Maud Daleskog, for all the hours you have spent on this project, your great ability to take 
care of the patients when they come to the lab, and your excellent laboratory expertise. 
Without you this project would not have been possible! Also, Maj-Christina Johansson, for 
invaluable laboratory expertise during the first years of the project. Also, Ragnhild Stålesen, 
for your excellent laboratory expertise and for your help with making the figures in Paper II. 
Charlotte Ander, Kajsa Sundqvist, Kathinka Leine, for expert technical assistance. 
Nailin Li, for expert knowledge in the flow cytometric method. 
All the APSIS investigators, without your great job, the first part of my project would not 
have been possible. 
  43 
Lena Landstedt-Hallin, Danderyd Hospital and Nils Adner, Södersjukhuset, for helping me 
in my search for patients to recruite. 
Björn Samnegård, head of the Department of Nephrology, Danderyd Hospital, for believing 
in me, encouraging me, providing research time and showing to everyone that you think my 
research is important. You are a great boss!  
All my colleagues at the Department of Nephrology, Danderyd Hospital, Guna Germanis, 
Anders Danielsson, Anna Fagergren, Boa Grönros, Elena Fedchenko, Eva Bång 
Bernstone, Josefin Mörtberg, Lysann Essinger, Annika Alvelius, Lars Edwall and Senka 
Sendic for your friendship, care and interest in my project. Having you as colleagues is a 
privilege, with all your knowledge and experience, and with all our laughs and inspiring 
conversations about almost anything, even when things are tough and we have a very busy 
working schedule. 
Sakke Rekola, my former ST supervisor, for introducing me to the field of nephrology, 
sharing all your broad experience and for your great subtle humor. I miss you! 
All the staff at the Department of Nephrology Danderyd Hospital, for making our clinic 
such a great and valuable place to work in. A special thanks to, Jeanette Wallin, research 
nurse, for help, support and inspiring conversations and to Anna Ström, for being so helpful, 
service minded and competent. 
Eva Wikström Jonsson, for saving me this summer when I was in urgent need for someone 
to examine me in Clinical Pharmacology. 
Jan and David, my brothers and their families, for being such great, caring, interesting, 
funny, smart and inspiring people. 
Magnus, my best friend, husband and soul mate, for always believing in me, always standing 
by me, all your immense love and support during all this time and for being such a great 
listener. Without you this thesis could not have happened. I promise you that I will now 
grumble less and live more! 
Johan, Sofia and Gustaf , my beloved, wonderful children, for putting up with me, loving 
me, supporting me and being so loyal, all these years. Every time I was ready to quit, you did 
not let me. A special thanks for all your expert help and support regarding computers and 
other technical stuff. You are the true meaning of my life, not platelets, I promise you that! 
Nils, my father, for always believing in me, loving me, supporting me and always accepting 
me for who I am.  
Åsa, my mother, you are present in my mind every day. Your smiling spirit hovers over me in 
my hectic everyday life, giving me confidence and strength.  
And of course, all other friends and relatives not mentioned here but must not be forgotten. 
You fill my life with inspiration, laughter and energy! 
 44 
The study was supported by the Swedish Research Council/Medicine, the Swedish Heart-Lung 
foundation, the regional Agreement on Medical Training and Clinical Research (ALF) between 
Stockholm County Council and the Karolinska Insitutet, and a Medical School Grant from Merck, 
Sharp and Dohme. 
 
  45 
10 REFERENCES 
Afkarian, M., M. C. Sachs, B. Kestenbaum, et al. Kidney disease and increased mortality risk 
in type 2 diabetes. J Am Soc Nephrol 2013;24:302-8. 
Ait-Oufella, H., S. Taleb, Z. Mallat, et al. Recent advances on the role of cytokines in 
atherosclerosis. Arterioscler Thromb Vasc Biol 2011;31:969-79. 
Al Suwaidi, J., D. N. Reddan, K. Williams, et al. Prognostic implications of abnormalities in 
renal function in patients with acute coronary syndromes. Circulation 2002;106:974-80. 
Alonso, A., F. L. Lopez, K. Matsushita, et al. Chronic kidney disease is associated with the 
incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. 
Circulation 2011;123:2946-53. 
Amabile, N., A. P. Guerin, A. Leroyer, et al. Circulating endothelial microparticles are 
associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc 
Nephrol 2005;16:3381-8. 
Amabile, N., A. P. Guerin, A. Tedgui, et al. Predictive value of circulating endothelial 
microparticles for cardiovascular mortality in end-stage renal failure: a pilot study. Nephrol 
Dial Transplant 2012;27:1873-80. 
Anavekar, N. S., J. J. McMurray, E. J. Velazquez, et al. Relation between renal dysfunction 
and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-95. 
Ando, M., A. Iwata, Y. Ozeki, et al. Circulating platelet-derived microparticles with 
procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int 
2002;62:1757-63. 
Antoniades, C., C. Bakogiannis, D. Tousoulis, et al. The CD40/CD40 ligand system: linking 
inflammation with atherothrombosis. J Am Coll Cardiol 2009;54:669-77. 
Ariens, R. A. Fibrin(ogen) and thrombotic disease. J Thromb Haemost 2013;11 Suppl 1:294-
305. 
Baber, U., J. Bander, R. Karajgikar, et al. Combined and independent impact of diabetes 
mellitus and chronic kidney disease on residual platelet reactivity. Thromb Haemost 
2013;110:118-23. 
Baigent, C., A. Keech, P. M. Kearney, et al. Efficacy and safety of cholesterol-lowering 
treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials 
of statins. Lancet 2005;366:1267-78. 
Baigent, C., M. J. Landray, C. Reith, et al. The effects of lowering LDL cholesterol with 
simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal 
Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92. 
Best, P. J., R. Lennon, H. H. Ting, et al. The impact of renal insufficiency on clinical 
outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 
2002;39:1113-9. 
Boccardo, P., G. Remuzzi and M. Galbusera. Platelet dysfunction in renal failure. Semin 
Thromb Hemost 2004;30:579-89. 
Bonetti, P. O., L. O. Lerman, C. Napoli, et al. Statin effects beyond lipid lowering--are they 
clinically relevant? Eur Heart J 2003;24:225-48. 
 46 
Bonomini, M., S. Dottori, L. Amoroso, et al. Increased platelet phosphatidylserine exposure 
and caspase activation in chronic uremia. J Thromb Haemost 2004;2:1275-81. 
Brambilla, M., M. Camera, D. Colnago, et al. Tissue factor in patients with acute coronary 
syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates. 
Arterioscler Thromb Vasc Biol 2008;28:947-53. 
Burger, D., S. Schock, C. S. Thompson, et al. Microparticles: biomarkers and beyond. Clin 
Sci (Lond) 2013;124:423-41. 
Cerletti, C., C. Tamburrelli, B. Izzi, et al. Platelet-leukocyte interactions in thrombosis. 
Thromb Res 2012;129:263-6. 
Charo, I. F. and M. B. Taubman. Chemokines in the pathogenesis of vascular disease. Circ 
Res 2004;95:858-66. 
Chronic Kidney Disease Prognosis, C., K. Matsushita, M. van der Velde, et al. Association of 
estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular 
mortality in general population cohorts: a collaborative meta-analysis. Lancet 
2010;375:2073-81. 
Colhoun, H. M., D. J. Betteridge, P. N. Durrington, et al. Primary prevention of 
cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin 
Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 
2004;364:685-96. 
Collins, R., J. Armitage, S. Parish, et al. MRC/BHF Heart Protection Study of cholesterol-
lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled 
trial. Lancet 2003;361:2005-16. 
Davi, G. and C. Patrono. Platelet activation and atherothrombosis. N Engl J Med 
2007;357:2482-94. 
Diamant, M., M. E. Tushuizen, M. N. Abid-Hussein, et al. Simvastatin-induced endothelial 
cell detachment and microparticle release are prenylation dependent. Thromb Haemost 
2008;100:489-97. 
Faure, V., L. Dou, F. Sabatier, et al. Elevation of circulating endothelial microparticles in 
patients with chronic renal failure. J Thromb Haemost 2006;4:566-73. 
Ferreiro, J. L., J. A. Gomez-Hospital and D. J. Angiolillo. Platelet abnormalities in diabetes 
mellitus. Diab Vasc Dis Res 2010;7:251-9. 
Furman, M. I., S. E. Benoit, M. R. Barnard, et al. Increased platelet reactivity and circulating 
monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll 
Cardiol 1998;31:352-8. 
Galkina, E. and K. Ley. Leukocyte recruitment and vascular injury in diabetic nephropathy. J 
Am Soc Nephrol 2006;17:368-77. 
Gawaz, M., H. Langer and A. E. May. Platelets in inflammation and atherogenesis. J Clin 
Invest 2005;115:3378-84. 
Ghasemzadeh, M. and E. Hosseini. Platelet-leukocyte crosstalk: Linking proinflammatory 
responses to procoagulant state. Thromb Res 2013;131:191-7. 
Gibson, C. M., R. L. Dumaine, E. V. Gelfand, et al. Association of glomerular filtration rate 
on presentation with subsequent mortality in non-ST-segment elevation acute coronary 
  47 
syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J 2004;25:1998-
2005. 
Go, A. S., G. M. Chertow, D. Fan, et al. Chronic kidney disease and the risks of death, 
cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305. 
Goldberg, R. B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, 
and imbalanced coagulation in development of diabetes and its complications. J Clin 
Endocrinol Metab 2009;94:3171-82. 
Granerus, G. and M. Aurell. Reference values for 51Cr-EDTA clearance as a measure of 
glomerular filtration rate. Scand J Clin Lab Invest 1981;41:611-6. 
Gremmel, T., M. Muller, S. Steiner, et al. Chronic kidney disease is associated with increased 
platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transplant 
2013;28:2116-22. 
Griffin, J. H., J. A. Fernandez and H. Deguchi. Plasma lipoproteins, hemostasis and 
thrombosis. Thromb Haemost 2001;86:386-94. 
Groop, P. H., M. C. Thomas, J. L. Moran, et al. The presence and severity of chronic kidney 
disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58:1651-8. 
Hamilton, D., P. Riley, U. Miola, et al. Total plasma clearance of 51Cr-EDTA: variation with 
age and sex in normal adults. Nucl Med Commun 2000;21:187-92. 
Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 
2005;352:1685-95. 
Henn, V., J. R. Slupsky, M. Grafe, et al. CD40 ligand on activated platelets triggers an 
inflammatory reaction of endothelial cells. Nature 1998;391:591-4. 
Hess, K. and P. J. Grant. Inflammation and thrombosis in diabetes. Thromb Haemost 
2011;105 Suppl 1:S43-54. 
Hjemdahl, P., S. V. Eriksson, C. Held, et al. Favourable long-term prognosis in stable angina 
pectoris: an extended follow-up of the Angina Prognosis study In Stockholm (APSIS). Heart 
2005; 
Hoffman, M. and D. M. Monroe, 3rd. A cell-based model of hemostasis. Thromb Haemost 
2001;85:958-65. 
Hu, H., N. Li, M. Yngen, et al. Enhanced leukocyte-platelet cross-talk in Type 1 diabetes 
mellitus: relationship to microangiopathy. J Thromb Haemost 2004;2:58-64. 
Jalal, D. I., M. Chonchol and G. Targher. Disorders of hemostasis associated with chronic 
kidney disease. Semin Thromb Hemost 2010;36:34-40. 
Jurk, K. and B. E. Kehrel. Platelets: physiology and biochemistry. Semin Thromb Hemost 
2005;31:381-92. 
Juutilainen, A., S. Kortelainen, S. Lehto, et al. Gender difference in the impact of type 2 
diabetes on coronary heart disease risk. Diabetes Care 2004;27:2898-904. 
Kalogirou, M., V. Tsimihodimos and M. Elisaf. Pleiotropic effects of ezetimibe: do they 
really exist? Eur J Pharmacol 2010;633:62-70. 
Kannel, W. B. and D. L. McGee. Diabetes and cardiovascular disease. The Framingham 
study. JAMA 1979;241:2035-8. 
 48 
Kannel, W. B. and P. W. Wilson. Risk factors that attenuate the female coronary disease 
advantage. Arch Intern Med 1995;155:57-61. 
Kinlay, S. Low-density lipoprotein-dependent and -independent effects of cholesterol-
lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 2007;49:2003-
9. 
Koren, M. J., P. Lundqvist, M. Bolognese, et al. Anti-PCSK9 monotherapy for 
hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of 
evolocumab. J Am Coll Cardiol 2014;63:2531-40. 
Kottgen, A., S. D. Russell, L. R. Loehr, et al. Reduced kidney function as a risk factor for 
incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc 
Nephrol 2007;18:1307-15. 
Lajer, M., I. Tarnow, A. D. Michelson, et al. Soluble CD40 ligand is elevated in type 1 
diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney 
function. Platelets 2010;21:525-32. 
Landray, M. J., D. C. Wheeler, G. Y. Lip, et al. Inflammation, endothelial dysfunction, and 
platelet activation in patients with chronic kidney disease: the chronic renal impairment in 
Birmingham (CRIB) study. Am J Kidney Dis 2004;43:244-53. 
Lee, W. L., A. M. Cheung, D. Cape, et al. Impact of diabetes on coronary artery disease in 
women and men: a meta-analysis of prospective studies. Diabetes Care 2000;23:962-8. 
Levey, A. S., J. P. Bosch, J. B. Lewis, et al. A more accurate method to estimate glomerular 
filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal 
Disease Study Group. Ann Intern Med 1999;130:461-70. 
Levey, A. S. and J. Coresh. Chronic kidney disease. Lancet 2012;379:165-80. 
Li, N., A. H. Goodall and P. Hjemdahl. Efficient flow cytometric assay for platelet-leukocyte 
aggregates in whole blood using fluorescence signal triggering. Cytometry 1999;35:154-61. 
Li, N., H. Hu, M. Lindqvist, et al. Platelet-leukocyte cross talk in whole blood. Arterioscler 
Thromb Vasc Biol 2000;20:2702-8. 
Li, N., N. H. Wallen and P. Hjemdahl. Evidence for prothrombotic effects of exercise and 
limited protection by aspirin. Circulation 1999;100:1374-9. 
Lievens, D., A. Zernecke, T. Seijkens, et al. Platelet CD40L mediates thrombotic and 
inflammatory processes in atherosclerosis. Blood 2010;116:4317-27. 
Lim, H. S., A. D. Blann and G. Y. Lip. Soluble CD40 ligand, soluble P-selectin, interleukin-
6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor 
intervention. Circulation 2004;109:2524-8. 
Lutz, J., J. Menke, D. Sollinger, et al. Haemostasis in chronic kidney disease. Nephrol Dial 
Transplant 2014;29:29-40. 
Mackman, N. The many faces of tissue factor. J Thromb Haemost 2009;7 Suppl 1:136-9. 
McCullough, K., P. Sharma, T. Ali, et al. Measuring the population burden of chronic kidney 
disease: a systematic literature review of the estimated prevalence of impaired kidney 
function. Nephrol Dial Transplant 2012;27:1812-21. 
McLaren, J. E. and D. P. Ramji. Interferon gamma: a master regulator of atherosclerosis. 
Cytokine Growth Factor Rev 2009;20:125-35. 
  49 
Mobarrez, F., J. Antovic, N. Egberg, et al. A multicolor flow cytometric assay for 
measurement of platelet-derived microparticles. Thromb Res 2010;125:e110-6. 
Mobarrez, F., N. Egberg, J. Antovic, et al. Release of endothelial microparticles in vivo 
during atorvastatin treatment; a randomized double-blind placebo-controlled study. Thromb 
Res 2012;129:95-7. 
Mobarrez, F., S. He, A. Broijersen, et al. Atorvastatin reduces thrombin generation and 
expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in 
patients with peripheral arterial occlusive disease. Thromb Haemost 2011;106:344-52. 
Moody, W. E., N. C. Edwards, M. Madhani, et al. Endothelial dysfunction and cardiovascular 
disease in early-stage chronic kidney disease: cause or association? Atherosclerosis 
2012;223:86-94. 
Navarro-Gonzalez, J. F., C. Mora-Fernandez, M. Muros de Fuentes, et al. Inflammatory 
molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 
2011;7:327-40. 
Nitsch, D., M. Grams, Y. Sang, et al. Associations of estimated glomerular filtration rate and 
albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ 2013;346:f324. 
Nomura, S., A. Shouzu, S. Omoto, et al. Effects of losartan and simvastatin on monocyte-
derived microparticles in hypertensive patients with and without type 2 diabetes mellitus. 
Clin Appl Thromb Hemost 2004;10:133-41. 
Osterud, B. Tissue factor/TFPI and blood cells. Thromb Res 2012;129:274-8. 
Owens, A. P., 3rd, J. R. Byrnes and N. Mackman. Hyperlipidemia, tissue factor, coagulation, 
and simvastatin. Trends Cardiovasc Med 2014;24:95-8. 
Owens, A. P., 3rd and N. Mackman. Microparticles in hemostasis and thrombosis. Circ Res 
2011;108:1284-97. 
Palmer, S. C., J. C. Craig, S. D. Navaneethan, et al. Benefits and harms of statin therapy for 
persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 
2012;157:263-75. 
Pawlak, K., J. Tankiewicz, M. Mysliwiec, et al. Tissue factor/its pathway inhibitor system 
and kynurenines in chronic kidney disease patients on conservative treatment. Blood Coagul 
Fibrinolysis 2009;20:590-4. 
Rehnqvist, N., P. Hjemdahl, E. Billing, et al. Effects of metoprolol vs verapamil in patients 
with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 
1996;17:76-81. 
Roberts, A. C. and K. E. Porter. Cellular and molecular mechanisms of endothelial 
dysfunction in diabetes. Diab Vasc Dis Res 2013;10:472-82. 
Ross, R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340:115-26. 
Sarnak, M. J. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 
2003;41:11-7. 
Schmidt, M. I., B. B. Duncan, A. R. Sharrett, et al. Markers of inflammation and prediction of 
diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. 
Lancet 1999;353:1649-52. 
 50 
Schonbeck, U. and P. Libby. Inflammation, immunity, and HMG-CoA reductase inhibitors: 
statins as antiinflammatory agents? Circulation 2004;109:II18-26. 
Schwabe, R. F., H. Engelmann, S. Hess, et al. Soluble CD40 in the serum of healthy donors, 
patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis 
(CAPD) patients. Clin Exp Immunol 1999;117:153-8. 
Shantsila, E., P. W. Kamphuisen and G. Y. Lip. Circulating microparticles in cardiovascular 
disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost 
2010;8:2358-68. 
Shlipak, M. G., L. F. Fried, M. Cushman, et al. Cardiovascular mortality risk in chronic 
kidney disease: comparison of traditional and novel risk factors. JAMA 2005;293:1737-45. 
Shlipak, M. G., J. A. Simon, D. Grady, et al. Renal insufficiency and cardiovascular events in 
postmenopausal women with coronary heart disease. J Am Coll Cardiol 2001;38:705-11. 
Siasos, G., D. Tousoulis, E. Oikonomou, et al. Inflammatory markers in hyperlipidemia: from 
experimental models to clinical practice. Curr Pharm Des 2011;17:4132-46. 
Siegel, R. D., A. Cupples, E. J. Schaefer, et al. Lipoproteins, apolipoproteins, and low-density 
lipoprotein size among diabetics in the Framingham offspring study. Metabolism 
1996;45:1267-72. 
Sommeijer, D. W., K. Joop, A. Leyte, et al. Pravastatin reduces fibrinogen receptor gpIIIa on 
platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost 
2005;3:1168-71. 
Stenvinkel, P. and A. Alvestrand. Inflammation in end-stage renal disease: sources, 
consequences, and therapy. Semin Dial 2002;15:329-37. 
Szummer, K., P. Lundman, S. H. Jacobson, et al. Relation between renal function, 
presentation, use of therapies and in-hospital complications in acute coronary syndrome: data 
from the SWEDEHEART register. J Intern Med 2010;268:40-9. 
Tehrani, S., F. Mobarrez, A. Antovic, et al. Atorvastatin has antithrombotic effects in patients 
with type 1 diabetes and dyslipidemia. Thromb Res 2010;126:e225-31. 
Tehrani, S., F. Mobarrez, P. E. Lins, et al. Impaired endothelium-dependent skin 
microvascular function during high-dose atorvastatin treatment in patients with type 1 
diabetes. Diab Vasc Dis Res 2013;10:483-8. 
Thijs, A., P. W. Nanayakkara, P. M. Ter Wee, et al. Mild-to-moderate renal impairment is 
associated with platelet activation: a cross-sectional study. Clin Nephrol 2008;70:325-31. 
Tonelli, M., C. Bohm, S. Pandeya, et al. Cardiac risk factors and the use of cardioprotective 
medications in patients with chronic renal insufficiency. Am J Kidney Dis 2001;37:484-9. 
Tonelli, M., C. Wanner and M. Kidney Disease: Improving Global Outcomes Lipid 
Guideline Development Work Group. Lipid management in chronic kidney disease: synopsis 
of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann 
Intern Med 2014;160:182. 
Tsimihodimos, V., E. Dounousi and K. C. Siamopoulos. Dyslipidemia in chronic kidney 
disease: an approach to pathogenesis and treatment. Am J Nephrol 2008;28:958-73. 
Tuttle, K. R., G. L. Bakris, R. W. Bilous, et al. Diabetic Kidney Disease: A Report From an 
ADA Consensus Conference. Am J Kidney Dis 2014;64:510-33. 
  51 
Undas, A., K. E. Brummel-Ziedins and K. G. Mann. Statins and blood coagulation. 
Arterioscler Thromb Vasc Biol 2005;25:287-94 
van der Velde, M., K. Matsushita, J. Coresh, et al. Lower estimated glomerular filtration rate 
and higher albuminuria are associated with all-cause and cardiovascular mortality. A 
collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011;79:1341-52. 
Versteeg, H. H., J. W. Heemskerk, M. Levi, et al. New fundamentals in hemostasis. Physiol 
Rev 2013;93:327-58. 
Weiner, D. E., H. Tighiouart, M. G. Amin, et al. Chronic kidney disease as a risk factor for 
cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. 
J Am Soc Nephrol 2004;15:1307-15. 
Woo, J. S., W. Kim, S. R. Lee, et al. Platelet reactivity in patients with chronic kidney disease 
receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: 
results of the effect of platelet inhibition according to clopidogrel dose in patients with 
chronic kidney disease (PIANO-2 CKD) randomized study. Am Heart J 2011;162:1018-25. 
Wright, R. S., G. S. Reeder, C. A. Herzog, et al. Acute myocardial infarction and renal 
dysfunction: a high-risk combination. Ann Intern Med 2002;137:563-70. 
Yagmur, E., R. D. Frank, J. Neulen, et al. Platelet Hyperaggregability is Highly Prevalent in 
Patients With Chronic Kidney Disease: An Underestimated Risk Indicator of 
Thromboembolic Events. Clin Appl Thromb Hemost 2013; 
Yngen, M., C. G. Ostenson, H. Hu, et al. Enhanced P-selectin expression and increased 
soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: 
evidence for platelet hyperactivity and chronic inflammation. Diabetologia 2004;47:537-40. 
 
